Document:

Exhibit 4.1

 

EXHIBIT 4.1

UNIT PURCHASE AGREEMENT

     This Unit Purchase Agreement (this “Agreement”), dated as of February 20, 2007,
is made by and among IDM Pharma, Inc., a Delaware corporation (the “Company”), and the
Purchasers listed on Exhibit A (each, a “Purchaser” and collectively, the “Purchasers”).

Recitals:

     A. The Company desires to consummate a private placement of the Company’s Common Stock and
warrants to purchase Common Stock on terms more fully set forth herein (the “Offering”).

     B. The Company and the Purchasers are executing and delivering this Agreement and conducting
the Offering in reliance upon the exemption from securities registration afforded by Section 4(2)
of the Securities Act and Rule 506 under Regulation D.

     C. The Purchasers desire to purchase and the Company desires to sell, upon the terms and
conditions stated in this Agreement, a minimum of $11,500,000, up to a maximum of $15,000,000 of
Common Stock and warrants to purchase Common Stock of the Company.

     D. The capitalized terms used herein and not otherwise defined have the meanings given them in
Article 10 hereof.

AGREEMENT

     In consideration of the premises and the mutual covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company
and the Purchasers (severally and not jointly) hereby agree as follows:

ARTICLE 1

PURCHASE AND SALE OF UNITS

     1.1 Purchase and Sale of Units. At the Closing the Company will issue and sell to each
Purchaser, and each Purchaser will, severally and not jointly, purchase from the Company the number
of shares of Common Stock of the Company (the “Shares”) and warrants substantially in the form
attached as Exhibit B (the “Warrants”) to purchase the number of shares of Common Stock set forth
opposite such Purchaser’s name on Exhibit A (the Shares, Warrants and Warrant Shares referred to
collectively as the “Units”). The purchase price for each Share shall be $2.82 (the “Share
Purchase Price”). The purchase price for each Warrant shall be $0.022 (together with the Share
Purchase Price, the “Purchase Price”). The exercise price for each Warrant Share shall be $3.243,
subject to adjustment pursuant to the terms of Section 5 of the Warrant. The Warrants shall be
exercisable during the period beginning on the Closing Date and ending five years from the Closing
Date.

1.

 

     1.2 Payment. At the Closing, each Purchaser will pay the aggregate Purchase Price set forth
opposite its name on Exhibit A hereof by wire transfer of immediately available funds in accordance
with the Company’s wire instructions set forth on Exhibit C hereto. The Company will deliver to
the Purchasers the Warrants and stock certificates representing the Shares against delivery of the
aggregate Purchase Price within five business days of the Closing Date.

     1.3 Closing Date. The closing of the transaction contemplated by this Agreement (the
“Closing”) will take place on or about February 20, 2007 (the “Closing Date”) and will be held at
the offices of the Company or at such other place as the parties agree.

ARTICLE 2

PURCHASER’S REPRESENTATIONS AND WARRANTIES

     Each Purchaser represents and warrants to the Company as of the date of this Agreement and as
of the Closing, severally and not jointly with respect to itself, himself or herself and its, his
or her purchase hereunder, that:

     2.1 Investment Purpose. The Purchaser is purchasing the Units for its own account and not
with a present view toward the public sale or distribution thereof.

     2.2 Accredited Purchaser Status. The Purchaser is an “accredited investor” as defined in Rule
501(a) of Regulation D. The Purchaser has executed and delivered the applicable portions of the
Investor Questionnaire in the form of Exhibit D to the Company. The Purchaser hereby represents
that, either by reason of the Purchaser’s business or financial experience, the Purchaser has the
capacity to protect the Purchaser’s own interests in connection with the purchase of the Units. In
addition, the Purchaser is capable of evaluating the merits and risks of its investment in the
Company and has the capacity to protect its own interest.

     2.3 Reliance on Exemptions. The Purchaser understands that the Units are being offered and
sold to it in reliance upon specific exemptions from the registration requirements of United States
federal and state securities laws and that the Company is relying upon the truth and accuracy of,
and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Purchaser set forth herein in order to determine the availability of such
exemptions and the eligibility of the Purchaser to acquire the Units.

     2.4 Information. The Purchaser has been furnished with all relevant materials relating to the
business, finances and operations of the Company necessary to make an investment decision, and
materials relating to the offer and sale of the Units, that have been requested by the Purchaser,
including, without limitation, the Company’s SEC Documents (as defined in Section 3.6). The
Purchaser has been afforded the opportunity to ask questions of the Company.

     2.5 Acknowledgement of Risk. The Purchaser acknowledges and understands that its investment
in the Units involves a significant degree of risk, including, without limitation, (i) the Company
remains a development stage business with limited operating history and requires substantial funds
in addition to the proceeds from the sale of the Units; (ii) an

2.

 

investment in the Company is speculative, and only Purchasers who can afford the loss of their entire investment
should consider investing in the Company and the Units; (iii) the Purchaser may not be able to
liquidate its investment; (iv) transferability of the Units is extremely limited; (v) in the event
of a disposition of the Units, the Purchaser could sustain the loss of its entire investment; and
(vi) the Company has not paid any dividends on its Common Stock since inception and does not
anticipate the payment of dividends in the foreseeable future. Such risks are more fully set forth
in the SEC Documents.

     2.6 Governmental Review. The Purchaser understands that no United States federal or state
agency or any other government or governmental agency has passed upon or made any recommendation or
endorsement of the Units or an investment therein.

     2.7 Transfer or Resale. The Purchaser understands that:

          (a) neither the Units nor their component securities have been and, except with respect to the
Shares and the Warrant Shares to the extent contemplated in Article 7 hereof, will not be
registered under the Securities Act or any applicable state securities laws and, consequently, the
Purchaser may have to bear the risk of owning the Units and/or their component securities for an
indefinite period of time because the Units and/or their component securities may not be
transferred unless (i) the resale of the Shares and the Warrant Shares is registered pursuant to an
effective registration statement under the Securities Act, as contemplated in Article 7; (ii) the
Purchaser has delivered to the Company an opinion of counsel (in form, substance and scope
customary for opinions of counsel in comparable transactions) to the effect that the Units and/or
their component securities to be sold or transferred may be sold or transferred pursuant to an
exemption from such registration; or (iii) the Units and/or their component securities are sold or
transferred pursuant to Rule 144;

          (b) any sale of the Units and/or their component securities made in reliance on Rule 144 may
be made only in accordance with the terms of Rule 144 and, if Rule 144 is not applicable, any
resale of the Units and/or their component securities under circumstances in which the seller (or
the person through whom the sale is made) may be deemed to be an underwriter (as that term is
defined in the Securities Act) may require compliance with some other exemption under the
Securities Act or the rules and regulations of the SEC thereunder; and

          (c) except as set forth in Article 7, neither the Company nor any other person is under any
obligation to register the resale of the Shares, the Warrants or the Warrant Shares under the
Securities Act or any state securities laws or to comply with the terms and conditions of any
exemption thereunder.

     2.8 Legends. The Purchaser understands that until such time as the Shares or the Warrant
Shares may be sold pursuant to Rule 144(k) under the Securities Act, or are sold pursuant to an
effective Registration Statement (as defined in Section 7.2) in compliance with the prospectus
delivery requirements of the Securities Act and reasonably sufficient notice and confirmation of
such sale are delivered to the Company, the certificates representing the Shares and the Warrant
Shares will bear a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of the certificates for such Shares and Warrant Shares):

3.

 

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES
MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR
THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SOLD OR TRANSFERRED PURSUANT TO
AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.

     2.9 Authorization; Enforcement. This Agreement has been duly and validly authorized, executed
and delivered on behalf of the Purchaser and represents the valid and binding obligations of the
Purchaser enforceable in accordance with its terms, subject to the effect of any applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the rights of
creditors generally and the application of general principles of equity.

     2.10 Residency. The Purchaser is a resident of the jurisdiction set forth immediately below
such Purchaser’s name on the signature pages hereto.

     2.11 No Short Sales. Between the time the Purchaser learned about the Offering and the public
announcement of the Offering, the Purchaser has not engaged in any short sales or similar
transactions with respect to the Common Stock, nor has the Purchaser, directly or indirectly,
caused any person or entity to engage in any short sales or similar transactions with respect to
the Common Stock.

     2.12 No Legal, Tax or Investment Advice. The Purchaser understands that nothing in this
Agreement or any other materials presented to the Purchaser in connection with the purchase and
sale of the Units constitutes legal, tax or investment advice. The Purchaser has consulted such
legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its purchase of the Units.

     2.13 Confidentiality. The Purchaser will hold in confidence all information concerning this
Agreement and the placement of the Units hereunder until the earlier of such time as (a) the
Company has made a public announcement concerning this Agreement and the placement of the Units
hereunder or (b) this Agreement is terminated.

     2.14 Acknowledgements Regarding Placement Agent Fees and Manner of Offering and Sale. The
Purchaser acknowledges that the Company may be required to pay certain placement agent fees to a
certain third party and in an amount previously communicated to the Purchasers in connection with
the Units being offered hereby. The Purchaser represents that (i) the Purchaser was contacted
regarding the sale of the Units by the Company (or an authorized agent or representative thereof)
with whom the Purchaser had a prior substantial pre-existing relationship and (ii) no Units were
offered or sold to it by means of any form of general solicitation or general advertising, and in
connection therewith the Purchaser did not: (A) receive or review any advertisement, article,
notice or other communication published in a newspaper or magazine or similar media or broadcast
over television or radio whether closed circuit, or generally available; or (B) attend any seminar
meeting or industry investor conference whose attendees were invited by any general solicitation or
general advertising.

4.

 

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

     The Company represents and warrants to the Purchasers as of the date of this Agreement and as
of the Closing that:

     3.1 Organization and Qualification. Each of the Company and its Subsidiaries is an entity
duly formed, validly existing and in good standing under the laws of the jurisdiction in which it
was formed, with full power and authority (corporate and other) to own, lease, use and operate its
properties and to carry on its business as and where now owned, leased, used, operated and
conducted. Each of the Company and its Subsidiaries is duly qualified to do business and is in
good standing in every jurisdiction in which the nature of the business conducted by it makes such
qualification necessary, except where the failure to be so qualified or in good standing would not
have a Material Adverse Effect.

     3.2 Authorization; Enforcement. (i) The Company has all requisite corporate power and
authority to enter into and to perform its obligations under this Agreement, to consummate the
transactions contemplated hereby and to issue the Units in accordance with the terms hereof; (ii)
the execution, delivery and performance of this Agreement by the Company and the consummation by it
of the transactions contemplated hereby (including without limitation the issuance of the Units)
have been duly authorized by the Company’s Board of Directors
(the “Board”) (or a committee of the
Board) and no further consent or authorization of the Company, the Board, or its stockholders is
required; (iii) this Agreement has been duly executed by the Company; and (iv) this Agreement
constitutes a legal, valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency,
reorganization, or moratorium or similar laws affecting the rights of creditors generally and the
application of general principles of equity.

     3.3 Capitalization. The capitalization of the Company is as described in the Company’s SEC
Documents (as defined in Section 3.6 below), subject to changes to such capitalization resulting
from issuances of shares of Common Stock pursuant to the Company’s equity incentive plans, 2001
Employee Stock Purchase Plan, Employee Stock Purchase Plan for employees of IDM S.A., Option
Liquidity Agreements, the Put/Call Agreements and outstanding Company warrants. All of such
outstanding shares of capital stock have been duly authorized, validly issued, fully paid and
nonassessable. No shares of capital stock of the Company, including the Units issuable pursuant to
this Agreement, are subject to preemptive rights or any other similar rights of the stockholders of
the Company or any liens or encumbrances imposed through the actions or failure to act of the
Company. All of the issued and outstanding shares of capital stock of the Company and each of its
Subsidiaries incorporated within in the United States were issued in compliance with applicable
state and federal securities laws, and with respect to its foreign Subsidiaries, with applicable
foreign securities laws. There are no (i) outstanding options, warrants, rights to subscribe for,
puts, calls, rights of first refusal, agreements, understandings, claims or other commitments or
rights of any character whatsoever relating to, or securities or rights convertible into,
exercisable for, or exchangeable for any shares of capital stock of the Company, or arrangements by
which the Company is or may become

5.

 

bound to issue additional shares of capital stock of the Company (excluding those rights that
have been waived) other than (a) 2,133,296 shares reserved for issuance or subject to outstanding
options under the Company’s equity incentive plans, (b) 41,643 shares reserved for issuance under
the Company’s 2001 Employee Stock Purchase Plan, (c) 30,714 shares reserved for issuance under the
IDM Employee Stock Purchase Plan for employees of Immuno-Designed Molecules, S.A., a société
anonyme organized under the laws of France (“IDM S.A.”), (d) 380,815 shares reserved for issuance
pursuant to the Option Liquidity Agreements between the Company and certain holders of IDM S.A.
stock options, (e) 44,291 shares reserved pursuant to the Put/Call Agreements, dated on or about
August 16, 2005, between the Company and certain IDM S.A. shareholders that hold such shares in a
plan d’épargne en actions (the “Put/Call Agreements”), and (f) 211,882 shares reserved for issuance
upon the exercise of the Company existing warrants; (ii) agreements or arrangements under which the
Company is obligated to register the sale of any of its securities under the Securities Act (except
as contemplated under Article 7) or the resale of its securities (except those obligations that
have been complied with) and (iii) anti-dilution or price (exercise, conversion, reset, exchange or
otherwise) adjustment provisions contained in any security issued by the Company (or in any
agreement providing rights to security holders) that will be triggered by the issuance of the Units
or the exercise of the Warrants. The Company has furnished or made available to the Purchasers
true and correct copies of the Company’s Amended and Restated Certificate of Incorporation, as
amended (the “Certificate of Incorporation”), as in effect on the date hereof, and the Company’s
Amended and Restated Bylaws (the “Bylaws”) as in effect on the date hereof.

     3.4 Issuance of Units. The Shares, the Warrants and all of the shares of Common Stock
issuable upon exercise of the Warrants (the “Warrant Shares”) are duly authorized and, upon
issuance in accordance with the terms of this Agreement and, as applicable, the Warrants, the
Shares and the Warrant Shares, will be validly issued, fully paid and non-assessable, free from all
taxes, liens, claims, encumbrances and charges with respect to the issue thereof, and will not be
subject to preemptive rights or other similar rights of stockholders of the Company.

3.5 No Conflicts; No Violation.

          (a) The execution, delivery and performance of this Agreement by the Company and the
consummation by the Company of the transactions contemplated hereby (including, without limitation,
the issuance of the Units) will not (i) conflict with or result in a violation of any provision of
its Certificate of Incorporation or Bylaws, (ii) violate or conflict with, or result in a breach of
any provision of, or constitute a default (or an event which with notice or lapse of time or both
could become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture, or instrument to which the Company is a party, or
(iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
United States federal and state securities laws and regulations and regulations of any
self-regulatory organizations to which the Company or its securities are subject) applicable to the
Company, except for such conflicts, breaches, defaults, terminations, amendments, accelerations,
cancellations and violations as would not, individually or in the aggregate, have a Material
Adverse Effect.

          (b) The Company is not in violation of its Certificate of Incorporation or Bylaws and the
Company is not in default under any agreement, indenture or instrument to

6.

 

which the Company is a party or by which any property or assets of the Company is bound or
affected, except as described in Section 3.17 and for possible defaults as would not, individually
or in the aggregate, have a Material Adverse Effect.

          (c) The Company is not conducting its business in violation of any law, ordinance or
regulation of any governmental entity, the failure to comply with which would, individually or in
the aggregate, have a Material Adverse Effect.

          (d) The Company is not required to obtain any consent, authorization or order of, or make any
filing or registration with, any court or governmental agency or any regulatory or self regulatory
agency (other than a Notification of Listing of Additional Shares with Nasdaq) in order for it to
execute, deliver or perform any of its obligations under this Agreement in accordance with the
terms hereof, or to issue and sell the Units in accordance with the terms hereof other than such as
have been made or obtained, and except for any filings required to be made under federal or state
securities laws. Except as indicated in the preceding sentence, all consents, authorizations,
orders, filings and registrations that the Company is required to obtain pursuant to the preceding
sentence have been obtained or effected on or prior to the Closing Date.

     3.6 SEC Documents, Financial Statements. The Company has timely filed all reports, schedules,
forms, statements and other documents required to be filed by it with the SEC during the twelve
(12) months preceding the date of this Agreement, pursuant to the reporting requirements of the
Exchange Act (all of the foregoing filed prior to the date hereof and all exhibits included therein
and financial statements and schedules thereto and documents (other than exhibits) incorporated by
reference therein, being hereinafter referred to herein as the “SEC Documents”) except for certain
forms the Company files on behalf of certain of its officers and directors required to be filed
pursuant to Section 16 of the Exchange Act. Each Purchaser has had access to true and complete
copies of the SEC Documents. As of their respective dates, the SEC Documents complied in all
material respects with the requirements of the Exchange Act or the Securities Act, as the case may
be, and the rules and regulations of the SEC promulgated thereunder applicable to the SEC
Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any
untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. There are no unresolved staff comments on such SEC
Documents. As of their respective dates, the financial statements of the Company included in the
SEC Documents complied as to form in all material respects with applicable accounting requirements
and the published rules and regulations of the SEC with respect thereto. Such financial statements
have been prepared in accordance with accounting principles generally accepted in the United
States, consistently applied, during the periods involved (except (i) as may be otherwise indicated
in such financial statements or the notes thereto, or (ii) in the case of unaudited interim
statements, to the extent they may not include footnotes or may be condensed or summary statements)
and fairly present in all material respects the financial position of the Company and its
Subsidiaries as of the dates thereof and the results of its operations and cash flows for the
periods then ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments). Except as set forth in the financial statements included in the SEC Documents, each
of the Company and its Subsidiaries has no liabilities, contingent or otherwise, other than
liabilities incurred in the ordinary course of business

7.

 

subsequent to September 30, 2006, and liabilities of the type not required under generally
accepted accounting principles to be reflected in such financial statements. Such liabilities
incurred subsequent to September 30, 2006, are not, in the aggregate, material to the financial
condition or operating results of the Company or its Subsidiaries.

     3.7 Absence of Litigation. There is no action, suit, claim, proceeding, inquiry or
investigation before or by any court, public board, government agency, self-regulatory organization
or body pending or, to the knowledge of the Company, threatened against or affecting the Company or
any of its officers or directors acting as such that if determined adversely to the Company could,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

     3.8 Intellectual Property Rights. The Company and its Subsidiaries own, or possess licenses
or sufficient rights to use, all patents, patent applications, patent rights, inventions, know-how,
trade secrets, trademarks, trademark applications, service marks, service names, trade names and
copyrights necessary to enable it to conduct its business as now operated and as proposed to be
operated as described in the SEC Documents (the “Intellectual Property”), except where the failure
to currently own or possess such rights could not reasonably be expected to have a Material Adverse
Effect. To the Company’s knowledge, all Intellectual Property of the Company and its Subsidiaries
is currently in compliance with all legal requirements (including timely filings, proofs and
payments of fees) and the Company’s and its Subsidiaries’ registered patents, registered trademarks
and registered copyrights are valid and enforceable. Except as set forth in the SEC Documents,
there are no material options, licenses or agreements relating to the Intellectual Property, nor is
the Company or its Subsidiaries bound by or a party to any material options, licenses or agreements
relating to the patents, patent applications, patent rights, inventions, know-how, trade secrets,
trademarks, trademark applications, service marks, service names, trade names or copyrights of any
other person or entity. All such options, licenses or agreements are valid and binding obligations
of the Company or its Subsidiaries, and to the Company’s knowledge, the other parties thereto,
enforceable in accordance with their terms. Neither the Company nor any of its Subsidiaries, nor
to the Company’s knowledge, any of the other parties thereto, is in material violation, breach or
default of any such options, licenses or agreements. Except as disclosed in the SEC Documents,
there is no claim or action or proceeding pending or, to the Company’s knowledge, threatened that
challenges the right of the Company with respect to any Intellectual Property. Except as described
in the SEC Documents, to the Company’s knowledge, the conduct of the Company’s and its
Subsidiaries’ businesses as now operated and as proposed to be operated as described in the SEC
Documents does not infringe or otherwise impair or conflict with (collectively, “Infringe”) any
Intellectual Property rights of any third party or any confidentiality obligation owed to a third
party except where the infringement, impairment or conflict could not reasonably be expected to
have a Material Adverse Effect and, to the Company’s knowledge, the Intellectual Property and
confidential information of the Company and its Subsidiaries which are necessary for the conduct of
Company’s and each of its Subsidiaries’ respective businesses as now operated and as proposed to be
operated as described in the SEC Documents are not being Infringed by any third party.

     3.9 Tax Status. Each of the Company and its Subsidiaries has timely made or filed all
federal, state and foreign income and all other tax returns, reports and declarations required

8.

 

by any jurisdiction to which it is subject (unless and only to the extent that the Company or
its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all
unpaid and unreported taxes) and has timely paid all taxes and other governmental assessments and
charges that are material in amount, shown or determined to be due on such returns, reports and
declarations, except those being contested in good faith, and has set aside on its books provisions
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which
such returns, reports or declarations apply. To the Company’s knowledge, there are no unpaid taxes
in any material amount claimed to be due by the taxing authority of any jurisdiction. Neither the
Company nor any of its Subsidiaries has executed a waiver with respect to the statute of
limitations relating to the assessment or collection of any foreign, federal, state or local tax.
None of the Company’s or its Subsidiaries’ tax returns is presently being audited by any taxing
authority.

     3.10 Environmental Laws. Each of the Company and its Subsidiaries (i) is in compliance in all
material respects with all applicable foreign, federal, state and local laws and regulations
relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants to which it is subject (“Environmental Laws”),
(ii) has received all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct its business and (iii) is in compliance with all terms and conditions
of any such permit, license or approval where, in each of the three foregoing clauses, the failure
to so comply would have, individually or in the aggregate, a Material Adverse Effect.

     3.11 Placement Agent. The Company has taken no action that would give rise to any claim by
any person for brokerage commissions, placement agent’s fees or similar payments relating to this
Agreement or the transactions contemplated hereby, except for dealings with the third party
described in Section 2.14, whose commissions and fees, as applicable, may be required to be paid by
the Company.

     3.12 Employment Matters. The Company is in compliance with all federal, state, local and
foreign laws and regulations respecting employment and employment practices, terms and conditions
of employment and wages and hours except where failure to be in compliance would not have a
Material Adverse Effect. The Company is not bound by or subject to (and none of its assets or
properties is bound by or subject to) any written or oral, express or implied, contract, commitment
or arrangement with any labor union, and no labor union has requested or, to the Company’s
knowledge, has sought to represent any of the employees, representatives or agents of the Company.
There is no strike or other labor dispute involving the Company pending, or to the Company’s
knowledge, threatened, that could have a Material Adverse Effect nor is the Company aware of any
labor organization activity involving its employees. The Company is not aware that any officer or
key employee intends to terminate his or her employment with the Company, nor does the Company have
a present intention to terminate the employment of any officer or key employee. Each employee,
consultant and contractor of the Company or any of its Subsidiaries who has had access to
confidential information which is necessary for the conduct of the Company’s and each of its
Subsidiaries’ respective businesses as now operated and as proposed to be operated as described in
the SEC Documents has executed an agreement to maintain the confidentiality of such confidential
information and has executed appropriate agreements that are substantially consistent with the
Company’s or its Subsidiaries’

9.

 

standard forms thereof. Each employee of the Company or any of its Subsidiaries has assigned
to the Company all rights to Intellectual Property necessary for the conduct of the Company’s and
each of its Subsidiaries’ respective businesses as now operated and as proposed to be operated as
described in the SEC Documents.

     3.13 Subsidiaries. IDM S.A. is a majority owned subsidiary of the Company. IDM, Inc., a
Delaware corporation, and IDM-Biotech Ltd., a Canadian company, are both wholly owned subsidiaries
of IDM S.A. (together, with IDM S.A., the “Subsidiaries”). Except for the Subsidiaries, the
Company does not presently own or control, directly or indirectly, any interest in any other
corporation, association, joint venture, partnership or other business entity and the Company is
not a direct or indirect participant in any joint venture or partnership.

     3.14 No Conflict of Interest. The Company is not indebted, directly or indirectly, to any of
its officers or directors or to their respective spouses or children, in any amount whatsoever
other than in connection with expenses or advances of expenses incurred in the ordinary course of
business or relocation expenses of employees. None of the Company’s officers, directors or
employees, or any members of their immediate families, are directly, or indirectly, indebted to the
Company (other than as described in the SEC Documents) or, to the Company’s knowledge, have any
direct or indirect ownership interest in any entity with which the Company is affiliated (other
than affiliations resulting solely from ownership of Common Stock of the Company) or with which the
Company has a business relationship, or any entity which competes with the Company, except that
officers, directors, employees and/or stockholders of the Company may own stock in any publicly
traded company that may compete with the Company. To the Company’s knowledge, none of the
Company’s officers, directors or employees or any members of their immediate families are, directly
or indirectly, interested in any material contract with the Company. The Company is not a
guarantor or indemnitor of any indebtedness of any other person or entity.

     3.15 S-3 Status. The Company currently meets the “registrant eligibility” requirements set
forth in the general instructions to Form S-3 to enable the registration of the resale of the
Registrable Securities; provided, however, that the Company does not currently meet the
requirements for a primary offering.

     3.16 No Registration. Assuming the accuracy of the representations and warranties made by, and
compliance with the covenants of, the Purchasers in Article 2 hereof, no registration of the Units
under the Securities Act is required in connection with the offer and sale of the Units by the
Company to the Purchasers as contemplated by this Agreement. There are no circumstances that would
cause this Offering to be integrated with prior offerings by the Company for purposes of the
Securities Act, or any applicable stockholder approval provisions, including without limitation
under the rules and regulations of Nasdaq, nor will the Company take any action or steps that would
cause the offering of the Units to be integrated with other offerings.

     3.17 Nasdaq Compliance. The Company’s Common Stock is registered pursuant to Section 12(g) of
the Exchange Act and is listed on Nasdaq, and the Company has taken no action designed to, or which
is reasonably likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act or delisting the Common Stock from Nasdaq. The

10.

 

Company is in, and has no reason to believe that it will not in the foreseeable future
continue to be in, compliance with Nasdaq listing and maintenance requirements; provided, however,
that the Company is not in compliance with the stockholders’ equity requirement for continued
listing on Nasdaq set forth in NASD Rule 4450(a)(3). The sale and issuance of the Units does not
require stockholder approval, including, without limitation, pursuant to the Nasdaq Marketplace
Rules.

     3.18 No Manipulation of Stock. The Company has not taken and will not, in violation of
applicable law, take any action outside the ordinary course of business designated to or that might
reasonably be expected to cause or result in unlawful manipulation of the price of the Common Stock
to facilitate the sale or resale of the Units.

     3.19 Listing. The Company shall comply with all requirements of the National Association of
Securities Dealers, Inc. (the “NASD”) with respect to the issuance of the Shares and the listing of
the Registrable Securities on Nasdaq.

     3.20 Use of Proceeds. The Company intends to use the net proceeds from the sale of the Units
for working capital and general corporate purposes. The Company may also use a portion of the
proceeds (expected to be approximately $135,000, assuming a purchase price of approximately $3.00
per share) to purchase ordinary shares of IDM S.A., equivalent to up to 44,291 shares of Common
Stock of the Company, held by certain individual shareholders in a plan d’épargne en actions
subject to the terms of the Put/Call Agreements.

     3.21 Internal Controls. Except as described in the SEC Documents: the Company is in material
compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently applicable to the
Company; the Company and its Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with
management’s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset
accountability, (iii) access to assets is permitted only in accordance with management’s general or
specific authorization, and (iv) the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate action is taken with respect to any
differences; and, the Company has established disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and
procedures to ensure that material information relating to the Company, including its Subsidiaries,
is made known to the certifying officers by others within those entities, particularly during the
period in which the Company’s most recently filed period report under the Exchange Act, as the case
may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of
the Company’s controls and procedures as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company
presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on
their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no
significant changes in the Company’s internal controls (as such term is defined in Item 307(b) of
Regulation S-K) or, to the Company’s knowledge, in other factors that could significantly adversely
affect the Company’s internal controls. The Company maintains and will continue to maintain a
standard system of accounting established

11.

 

and administered in accordance with GAAP and the applicable requirements of the Exchange Act.

     3.22 Disclosures. Neither the Company nor any person or entity acting on its behalf has
provided the Purchasers or their agents or counsel with any information that constitutes or might
constitute material, non-public information. The written materials delivered to the Purchasers in
connection with the transactions contemplated by the Transaction Documents do not contain any
untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements contained therein, in light of the circumstances under which they were made, not
misleading.

     3.23 FDA Matters. The Company has not received any notice or other communication from the
United States Food and Drug Administration (“FDA”) indicating that the FDA will ultimately prohibit
the marketing, sale, license or use in the United States of any product currently being developed,
produced or marketed by the Company (“Product”), or that the FDA will materially delay approval of
marketing and sale of the Product in the United States. The Company has not received any notice or
other communication from the FDA or any other federal, state or foreign governmental entity
alleging any violation by the Company of any law, regulation or other legal provision applicable to
a Product. Each Product of the Company is, to its knowledge, being researched, developed,
manufactured, tested, distributed and/or marketed in compliance in all material respects with all
applicable requirements under the Federal Food, Drug and Cosmetic Act and the regulations
thereunder and similar laws and regulations applicable to such Product.

     3.24 Option Matters. Each option or other right to acquire Common Stock or other equity of
the Company (i) has an exercise price at least equal to the fair market value of the underlying
equity as of the date such option or other right was granted in all material respects in accordance
with all governing documents and in compliance with all applicable law, (ii) has no feature for the
deferral of compensation other than the deferral of recognition of income until the later of
exercise or disposition of such Company option or other right and (iii) has a grant date
represented for each option that is the date the option would be considered granted for tax,
corporate law and under generally accepted accounting principles.

     3.25 No Changes. Since September 30, 2006, except as identified and described in the SEC
Documents, there has not been (i) any material adverse change in the financial condition, earnings
or earnings prospects of the Company or its Subsidiaries (except as described in Section 3.17 and
as a result of the Company’s use of cash in the ordinary course of business and need to secure
financing for its ongoing operations), (ii) any material adverse event resulting in a Material
Adverse Effect for the Company or its Subsidiaries, (iii) any obligation, direct or contingent,
that is material to the Company or its Subsidiaries, incurred by the Company or its Subsidiaries,
except obligations incurred in the ordinary course of business, (iv) any dividend or distribution
of any kind declared, paid or made on the capital stock of the Company or its Subsidiaries, or (v)
any loss or damage (whether or not insured) to the property of the Company or its Subsidiaries
which has been sustained which has had or could reasonably be expected to have a Material Adverse
Effect.

12.

 

     3.26 Foreign Corrupt Practices. Neither the Company nor its Subsidiaries, nor to the
knowledge of the Company, any agent or other person acting on behalf of the Company or its
Subsidiaries, has (i) directly or indirectly, used any corporate funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any
foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose
fully any contribution made by the Company or its Subsidiaries (or made by any person acting on its
behalf of which the Company or its Subsidiaries is aware) which is in violation of law, or (iv)
violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as
amended.

ARTICLE 4

COVENANTS

     4.1 Reporting Status. During the Registration Period (as defined in Section 7.5(a)), the
Company will timely file all documents with the SEC, and the Company will not terminate its status
as an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules
and regulations thereunder would permit such termination.

     4.2 Expenses. The Company and each Purchaser is liable for, and will pay, its own expenses
incurred in connection with the negotiation, preparation, execution and delivery of this Agreement,
including, without limitation, attorneys’ and consultants’ fees and expenses; provided, however,
that the Company shall, at the Closing, reimburse the reasonable fees and expenses of the
Purchasers (including, without limitation, attorneys’ and consultants’ fees and expenses) in an
amount not to exceed Fifty Thousand Dollars ($50,000).

     4.3 Nasdaq Listing. The Company will use commercially reasonable efforts to continue the
listing and trading of its Common Stock on Nasdaq and, in accordance, therewith, will use
commercially reasonable efforts to comply in all respects with the Company’s reporting, filing and
other obligations under the bylaws or rules of such market or exchange, as applicable.

     4.4 Financial Information. The financial statements of the Company to be included in any
documents filed with the SEC will be prepared in accordance with accounting principles generally
accepted in the United States, consistently applied, and will fairly present in all material
respects the consolidated financial position of the Company and results of its operations and cash
flows as of, and for the periods covered by, such financial statements (subject, in the case of
unaudited statements, to normal year-end audit adjustments).

     4.5 Compliance with Law. As long as a Purchaser owns any of the Units, the Company will
conduct its business in compliance with all applicable laws, rules and regulations of the
jurisdictions in which it is conducting business (including, without limitation, all applicable
local, state and federal environmental laws and regulations), the failure to comply with which
would have a Material Adverse Effect.

     4.6 Reservation of Stock. The Company shall at all times reserve and keep available out of
its authorized but unissued shares of Common Stock, solely for the purpose of providing

13.

 

for the exercise of the Warrants, such number of shares of Common Stock as shall from time to
time equal the number of shares sufficient to permit the exercise of the Warrants issued pursuant
to this Agreement in accordance with their respective terms.

     4.7 Sales by Purchasers. Each Purchaser will sell any Units (and components thereof) held by
it in compliance with applicable prospectus delivery requirements, if any, or otherwise in
compliance with the requirements for an exemption from registration under the Securities Act and
the rules and regulations promulgated thereunder. No Purchaser will make any sale, transfer or
other disposition of the Units (or components thereof) in violation of federal or state securities
laws. Whenever the Company is required to cause unlegended certificates to replace previously
issued legended certificates, if unlegended certificates are not delivered to a Purchaser within
three (3) Business Days of submission by that Purchaser of legended certificate(s) to the Company’s
transfer agent together with a representation letter in customary form reasonably acceptable to the
transfer agent, the Company shall be liable to the Purchaser for liquidated damages in an amount
equal to one-thirtieth (1/30) of 1.5% of the aggregate Purchase Price of the Shares and Warrant
Shares evidenced by such certificate(s) for each day beyond such three (3) Business Days that the
unlegended certificates have not been so delivered (the “Delivery Penalty”). The Company shall
deliver said cash payment to the Purchaser by the fifth Business Day after the end of such period.
The Purchasers agree that to the extent it is finally adjudicated by a court of competent
jurisdiction or another alternative dispute resolution proceeding acceptable to the parties that
the Purchasers are entitled to payments from the Company with respect to any actions, causes of
action, suits, claims, losses, costs, penalties, fees, liabilities, damages, or expenses arising in
connection with this Section 4.7, the amount of such payments shall be offset by the amount of any
previous Delivery Penalty paid by the Company.

     4.8 Purchaser Lockups. For a period beginning on the Closing Date and ending 90 days after
the Closing Date, each Purchaser will not, directly or indirectly, (i) offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant for the sale of, make any short sale or otherwise dispose of or
transfer any Units (or components thereof), or (ii) enter into any swap or any other agreement or
any transaction that transfers, in whole or in part, directly or indirectly, the economic
consequence of ownership of any Units (or components thereof), whether any such swap or transaction
is to be settled by delivery of Units (or components thereof) or other securities, in cash or
otherwise (each of the above actions referred to herein as a “Disposition”). The foregoing
restriction is expressly intended to preclude each Purchaser from engaging in any hedging or other
transaction which is designed to or which reasonably could be expected to lead to or result in a
sale or disposition of any Purchaser’s Units (or components thereof) even if such securities would
be disposed of by someone other than Purchaser. Such prohibited hedging or other transaction would
include without limitation any short sale or any purchase, sale or grant of any right (including
without limitation any put or call option) with respect to any of Purchaser’s Units (or components
thereof) or with respect to any security that includes, relates to, or derives any significant part
of its value from such Units (or components thereof).

     4.9 Share Certificates. The Company shall use commercially reasonable efforts to cause its
transfer agent to issue certificates representing the Shares in the names of the Purchasers or
their designees within five (5) Business Days of the Closing. For the avoidance of

14.

 

doubt, the transfer agent’s failure to deliver the certificates representing the Shares within
such five (5) Business Days shall not give rise to any Delivery Penalty.

ARTICLE 5

PURCHASER CLOSING CONDITIONS

     The obligations of each Purchaser to consummate the transactions contemplated hereby shall be
subject to the satisfaction or waiver of each of the following conditions:

     5.1 Legal Opinion. The Company’s counsel shall have delivered a legal opinion to each
Purchaser in substantially the form set forth as Exhibit E.

     5.2 Hart-Scott-Rodino Act. The Company shall have made all necessary filings, if any,
required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

     5.3 Board Approval. The Board (or a duly authorized committee of the Board) shall have
approved this Agreement and all transactions and actions contemplated hereby.

     5.4 Aggregate Investment. The Company shall have received funds at the Closing for an
aggregate investment amount equal to or exceeding $11,500,000.

     5.5 Representations and Warranties. The representations and warranties made by the Company in
Section 3 hereof qualified as to materiality shall be true and correct at all times prior to and as
of the Closing, except to the extent any such representation or warranty expressly speaks as of an
earlier date, in which case such representation or warranty shall be true and correct as of such
earlier date, and, the representations and warranties made by the Company in Section 3 hereof not
qualified as to materiality shall be true and correct in all material respects at all times prior
to and as of the Closing, except to the extent any such representation or warranty expressly speaks
as of an earlier date, in which case such representation or warranty shall be true and correct in
all material respects as of such earlier date. The Company shall have performed in all material
respects all obligations and conditions herein required to be performed or observed by it on or
prior to the Closing.

     5.6 Consents. The Company shall have obtained any and all consents, permits, approvals,
registrations and waivers necessary or appropriate for consummation of the purchase and sale of the
Units and the consummation of the other transactions contemplated by this Agreement to be
consummated on or prior to the Closing, all of which shall be in full force and effect.

     5.7 No Judgments. No judgment, writ, order, injunction, award or decree of or by any court,
or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any
governmental authority, shall have been issued, and no action or proceeding shall have been
instituted by any governmental authority, enjoining or preventing the consummation of the
transactions contemplated hereby.

15.

 

     5.8 Stop Orders. No stop order or suspension of trading shall have been imposed by Nasdaq,
the SEC or any other governmental or regulatory body with respect to public trading in the
Company’s Common Stock.

     5.9 Certifications. The Company shall have delivered a Certificate, executed on behalf of the
Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing,
certifying to the fulfillment of the conditions specified in Sections 5.3 through 5.8. The Company
shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of
the Closing, certifying the resolutions adopted by the Board of Directors of the Company approving
the transactions contemplated by this Agreement, certifying the current versions of the Certificate
of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of
persons signing this Agreement and related documents on behalf of the Company.

ARTICLE 6

COMPANY CLOSING CONDITIONS

     The obligations of the Company to consummate the transactions contemplated hereby shall be
subject to the satisfaction or waiver of each of the following conditions:

     6.1 Receipt of Funds. The Company shall have received immediately available funds in the full
amount of the Purchase Price as set forth opposite each Purchaser’s name on Exhibit A hereto.

ARTICLE 7

REGISTRATION RIGHTS

     7.1 As used in this Article 7, the following terms shall have the following meanings:

          (a) “Business Day” means a day Monday through Friday on which banks are generally open for
business in the State of California.

          (b) “Filing Date” has the meaning set forth in Section 7.2.

          (c) “Final Prospectus” has the meaning set forth in Section 7.7(a).

          (d) “Holders” means any Purchaser holding Registrable Securities or any person to whom the
rights under Article 7 have been transferred in accordance with Section 7.10 hereof.

          (e) “Indemnified Party” has the meaning set forth in Section 7.7(c).

          (f) “Indemnifying Party” has the meaning set forth in Section 7.7(c).

16.

 

           (g) “Person” means any person, individual, corporation, limited liability company,
partnership, trust or other nongovernmental entity or any governmental agency, court, authority or
other body (whether foreign, federal, state, local or otherwise).

          (h) The terms “register,” “registered” and “registration” refer to the registration effected
by preparing and filing a registration statement in compliance with the Securities Act, and the
declaration or ordering of the effectiveness of such registration statement.

          (i) “Registrable Securities” means (i) the Shares and (ii) the Warrant Shares; provided,
however, that securities shall only be treated as Registrable Securities if and only for so long as
they (A) have not been disposed of pursuant to a registration statement declared effective by the
SEC, (B) have not been sold in a transaction exempt from the registration and prospectus delivery
requirements of the Securities Act so that all transfer restrictions and restrictive legends with
respect thereto are removed upon the consummation of such sale or (C) are held by a Holder.

          (j) “Registration End Date” means the earliest of the following: (i) such time as all of the
Registrable Securities are sold, (ii) the second anniversary of the date the Registration Statement
filed in accordance with Section 7.2 hereof is first declared effective, or (iii) the date all
Registrable Securities may be sold under Rule 144 during any 90 day period.

          (k) “Registration Expenses” means all expenses (other than Selling Expenses) incurred by the
Company in complying with Section 7.2 hereof, including, without limitation, all registration,
qualification and filing fees, printing expenses, escrow fees, fees and expenses of counsel for the
Company, blue sky fees and expenses and the expense of any special audits incident to or required
by any such registration.

          (l) “Registration Statement” has the meaning set forth in Section 7.2.

          (m) “Registration Period” has the meaning set forth in Section 7.5(a).

          (n) “Selling Expenses” means all underwriting discounts and selling commissions applicable to
the sale of Registrable Securities and all fees and expenses of legal counsel for any Holder.

     7.2 As soon as reasonably practicable, but in no event later than 30 days after the Closing
Date (the “Filing Date”), the Company shall file a registration statement covering the resale of
the Registrable Securities on a Form S-3 Registration Statement (the “Registration Statement”) with
the SEC and effect the registration, qualifications or compliances (including, without limitation,
the execution of any required undertaking to file post-effective amendments, appropriate
qualifications or exemptions under applicable blue sky or other state securities laws and
appropriate compliance with applicable securities laws, requirements or regulations) as promptly as
practicable after the filing thereof, but in any event on or before the date which is 90 days after
the Closing Date. The Company shall not be obligated to enter into any underwriting agreement for
the sale of any of the Registrable Securities pursuant to this Section 7.2. The Company shall
supply legal counsel selected by the Purchasers with one (1) copy of each Registration Statement
filed pursuant to this Article 7 prior to filing with the Commission to afford counsel a reasonable
opportunity to review and comment upon such Registration

17.

 

Statement. The Company shall reasonably cooperate with such legal counsel in performing the
Company’s obligations under this Article 7.

     7.3 All Registration Expenses incurred in connection with any registration, qualification,
exemption or compliance pursuant to Section 7.2 shall be borne by the Company. All Selling
Expenses relating to the sale of securities registered by or on behalf of Holders shall be borne by
such Holders pro rata on the basis of the number of securities so registered, provided that that
the Company will pay the reasonable fees and expenses of one counsel to the selling Purchasers, not
to exceed $15,000, in connection with each registration pursuant to Section 7.2.

     7.4 The Company further agrees that, in the event that the Registration Statement to be filed
under Section 7.2 hereof (i) has not been filed with the SEC within 30 days after the Closing Date,
(ii) has not been declared effective by the SEC within 90 days after the Closing Date, provided
however, that such 90 day period shall be extended by up to 60 additional days if such delay in
effectiveness is due to a determination by the SEC not to declare the Registration Statement
effective, and such determination does not directly result from the Company’s failure to promptly
respond to any SEC comments to the Registration Statement or the Company’s failure to act on any
other matter that is within the Company’s sole control, (iii) has not been declared effective by
the SEC within 5 days after the Company or its counsel is notified by the SEC that (A) the SEC will
not review the Registration Statement or (B) the Company has addressed all comments and questions
posed by the SEC staff with respect to the SEC’s review of the Registration Statement to the
satisfaction of the SEC staff, (iv) after being declared effective by the SEC, ceases thereafter to
be current, effective and available to the Purchasers for use in the lawful resale of the
Registrable Securities, through no fault of the Company or election thereby to suspend the
effectiveness of the Registration Statement pursuant to Section 7.8(b), for any consecutive 10-day
period or for 30 days within any 365-day period, provided however, that any one or more days during
which the use of the Registration Statement is suspended pursuant to and in accordance with Section
7.8(b) shall not be counted for purposes of calculating the foregoing consecutive 10-day period or
30 days within any 365-day period, provided further, however, that it is understood that the
Company shall not be entitled to rely on an Allowed Delay in Section 7.8(b) and this Section
7.4(iv) in a cumulative manner for any event or circumstance or series of related events or
circumstances to extend the period during which penalties are not assessed on the Company, (v)
after being declared effective by the SEC, ceases thereafter to be current, effective and available
to the Purchasers for more than the 20-day period allowed pursuant to Section 7.8(b), or (vi) is
declared effective by the SEC, and the Holders thereafter have resold Registrable Securities
pursuant to the Registration Statement in compliance with the prospectus delivery requirements of
the Securities Act and provided reasonably sufficient confirmation of such sale to the Company, and
the Company shall fail to deliver to the applicable Holders or their authorized representatives
unlegended stock certificates within 3 Business Days of the Company’s receipt of confirmation of
such sale (each such event referred to in clauses (i) through (vi), a “Registration Default”), then
the Company shall pay to each Purchaser 1.5% of the Share Purchase Price of such Purchaser’s Units
that are still outstanding and held by such Purchaser (a “Penalty”), for each 30 day period (or
portion thereof) during which the Registration Default remains uncured. The Company shall deliver
said cash payment to the Purchaser by the fifth Business Day after the end of such period.
Notwithstanding the foregoing, no Registration Default shall be deemed to occur with respect to the
Company’s responsibilities hereunder to a Holder and no Penalty shall be paid by the Company
hereunder to such Holder if

18.

 

the failure by the Company to meet the deadlines set forth in this Section 7.4 results from
the failure of such Holder to provide the Company with the information required by Section 7.8(c)
herein in a reasonably timely manner. For the avoidance of doubt, and notwithstanding any other
provision of this Agreement to the contrary, in no event shall the total amount of any and all
Penalties payable by the Company to any Purchaser pursuant to this Section 7.4, exceed 12% of the
aggregate Purchase Price attributable to the Units outstanding and held by such Purchaser hereunder
for each 365 day period following the Closing Date. The Purchasers agree that to the extent it is
finally adjudicated by a court of competent jurisdiction or another alternative dispute resolution
proceeding acceptable to the parties that the Purchasers are entitled to payments from the Company
with respect to any actions, causes of action, suits, claims, losses, costs, penalties, fees,
liabilities, damages, or expenses arising in connection with this Section 7.4, the amount of such
payments shall be offset by the amount of any previous Penalty paid by the Company.

     7.5 In the case of the registration, qualification, exemption or compliance effected by the
Company pursuant to this Agreement, the Company shall, upon reasonable written request, inform each
Holder as to the status of such registration, qualification, exemption and compliance. At its
expense the Company shall:

          (a) use its best efforts to keep such registration, and any qualification, exemption or
compliance under state securities laws which the Company determines to obtain, continuously
effective until the Registration End Date, subject to Section 7.8; provided, however, that in the
event that the Company suspends the effectiveness of a registration pursuant to Section 7.8(b)
hereof, the applicable time period during which the Registration Statement is to remain effective
shall be extended by a period of time equal to the duration of the period of such suspension. The
period of time during which the Company is required hereunder to keep the Registration Statement
effective is referred to herein as the “Registration Period.”

          (b) advise the Holders within five Business Days:

               (i) when the Registration Statement or any amendment thereto has been filed with the SEC and
when the Registration Statement or any post-effective amendment thereto has become effective;

               (ii) of any request by the SEC for amendments or supplements to the Registration Statement or
the prospectus included therein or for additional information;

               (iii) of the issuance by the SEC of any stop order suspending the effectiveness of the
Registration Statement or the initiation of any proceedings for such purpose;

               (iv) of the receipt by the Company of any notification with respect to the suspension of the
qualification of the Registrable Securities included therein for sale in any jurisdiction or the
initiation or threatening of any proceeding for such purpose; and

               (v) of the occurrence of any event that requires the making of any changes in the Registration
Statement or the prospectus so that, as of such date, the statements therein are not misleading and
do not omit to state a material fact required to be stated therein or necessary to make the
statements therein (in the case of the prospectus, in the light of the circumstances under which
they were made) not misleading;

19.

 

          (c) use its commercially reasonable efforts to obtain the withdrawal of any order suspending
the effectiveness of any Registration Statement at the earliest possible time;

          (d) promptly furnish to each Holder, without charge, at least one copy of such Registration
Statement and any post-effective amendment thereto, including financial statements and schedules,
and, if the Holder so requests in writing, all exhibits in the form filed with the SEC;

          (e) during the Registration Period, promptly deliver to each Holder, without charge, as many
copies of the prospectus included in such Registration Statement and any amendment or supplement
thereto as such Holder may reasonably request; and the Company consents to the use, consistent with
the provisions hereof and thereof, of the prospectus or any amendment or supplement thereto by each
of the selling Holders of Registrable Securities in connection with the offering and sale of the
Registrable Securities covered by the prospectus or any amendment or supplement thereto. In
addition, upon the reasonable request of the Holder and subject in all cases to confidentiality
protections reasonably acceptable to the Company, the Company will meet with a Holder or a
representative thereof at the Company’s headquarters to discuss all information relevant for
disclosure in the Registration Statement covering the Registrable Securities, and will otherwise
cooperate with any Holder conducting an investigation for the purpose of reducing or eliminating
such Holder’s exposure to liability under the Securities Act, including the reasonable production
of information at the Company’s headquarters;

          (f) during the Registration Period, promptly deliver to each Holder, without charge, (i) as
soon as practicable (but in the case of the annual report of the Company to its stockholders,
within 120 days after the end of each fiscal year of the Company) one copy of the following
documents, other than those documents available via EDGAR: (A) its annual report to its
stockholders, if any (which annual report shall contain financial statements audited in accordance
with generally accepted accounting principles in the United States of America by a firm of
certified public accountants of recognized standing); (B) if not included in substance in its
annual report to stockholders, its annual report on Form 10-K (or similar form); (C) each of its
quarterly reports to its stockholders, and, if not included in substance in its quarterly reports
to stockholders, its quarterly report on Form 10-Q (or similar form), and (D) a copy of the full
Registration Statement (the foregoing, in each case, excluding exhibits); and (ii) upon reasonable
request, all exhibits excluded by the parenthetical to the immediately preceding clause (D), and
all other information that is generally available to the public;

          (g) prior to any public offering of Registrable Securities pursuant to any Registration
Statement, promptly take such actions as may be necessary to register or qualify or obtain an
exemption for offer and sale under the securities or blue sky laws of such jurisdictions as any
such Holders reasonably request in writing, provided that the Company shall not for any such
purpose be required to qualify generally to transact business as a foreign corporation in any
jurisdiction where it is not so qualified or to consent to general service of process in any such
jurisdiction, and do any and all other acts or things reasonably necessary or advisable to enable
the offer and sale in such jurisdictions of the Registrable Securities covered by such Registration
Statement;

20.

 

          (h) upon the occurrence of any event contemplated by Section 7.5(b)(v) above, the
Company shall use its commercially reasonable efforts to promptly prepare a post-effective
amendment to the Registration Statement or a supplement to the related prospectus, or file any
other required document so that, as thereafter delivered to purchasers of the Registrable
Securities included therein, the prospectus will not include any untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein, in the light of
the circumstances under which they were made, not misleading;

          (i) otherwise use its commercially reasonable efforts to comply with all applicable rules and
regulations of the SEC which could affect the sale of the Registrable Securities;

          (j) use its commercially reasonable efforts to cause all Registrable Securities to be listed
on each securities exchange or market, if any, on which equity securities issued by the Company
have been listed; and

          (k) use its commercially reasonable efforts to take all other steps necessary to effect the
registration of the Registrable Securities contemplated hereby and to enable the Holders to sell
Registrable Securities under Rule 144.

     7.6 The Holders shall have no right to take any action to restrain, enjoin or otherwise delay
any registration pursuant to Section 7.2 hereof as a result of any controversy that may arise with
respect to the interpretation or implementation of this Agreement.

     7.7 (a) To the extent permitted by law, the Company shall indemnify each Holder and each
person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect
to which any registration that has been effected pursuant to this Agreement, against all claims,
losses, damages and liabilities (or action in respect thereof), including any of the foregoing
incurred in settlement of any litigation, commenced or threatened (subject to Section 7.7(c)
below), arising out of or based on (i) any untrue statement (or alleged untrue statement) of a
material fact contained in the Registration Statement, prospectus, any amendment or supplement
thereof, or other document incident to any such registration, qualification or compliance or based
on any omission (or alleged omission) to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, in light of the circumstances
in which they were made, (ii) any violation by the Company of the Securities Act, any other
securities law, including any state securities law, or any rule or regulation thereunder relating
to the offer or sale of the Units, or (iii) any failure by the Company to fulfill any undertaking
included in the Registration Statement as amended at the time of effectiveness, and will reimburse
each Holder and each person controlling such Holder, for reasonable legal and other expenses
reasonably incurred in connection with investigating or defending any such claim, loss, damage,
liability or action as incurred; provided that the Company will not be liable in any such case to
the extent that any untrue statement or omission or allegation thereof is made in reliance upon and
in conformity with written information furnished to the Company by or on behalf of such Holder and
stated to be specifically for use in preparation of such Registration Statement, prospectus, any
amendment or supplement thereof, or other document incident to any such registration, qualification
or compliance; provided further, that the Company will not be liable in any such case where the
claim, loss, damage or

21.

 

liability arises out of or is related to the failure of the Holder to comply with the
covenants and agreements contained in this Agreement respecting sales of Registrable Securities,
and except that the foregoing indemnity agreement is subject to the condition that, insofar as it
relates to any such untrue statement or alleged untrue statement or omission or alleged omission
made in the preliminary prospectus but eliminated or remedied in the amended prospectus on file
with the SEC at the time the Registration Statement becomes effective or in the amended prospectus
filed with the SEC pursuant to Rule 424(b) or in the prospectus subject to completion under Rule
434 of the Securities Act, which together meet the requirements of Section 10(a) of the Securities
Act (the “Final Prospectus”), such indemnity shall not inure to the benefit of any such Holder or
any such controlling person, if a copy of the Final Prospectus furnished by the Company to the
Holder for delivery was not furnished to the person or entity asserting the loss, liability, claim
or damage at or prior to the time such furnishing is required by the Securities Act and the Final
Prospectus would have cured the defect giving rise to such loss, liability, claim or damage.

          (b) Each Holder will severally (but not jointly), if Registrable Securities held by such
Holder are included in the securities as to which such registration is being effected, indemnify
the Company, each of its directors and officers and each person who controls the Company within the
meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities
(or actions in respect thereof), including any of the foregoing incurred in settlement of any
litigation, commenced or threatened (subject to Section 7.7(c) below), arising out of or based on
any untrue statement (or alleged untrue statement) of a material fact contained in the Registration
Statement, prospectus, or any amendment or supplement thereof, incident to any such registration,
or based on any omission (or alleged omission) to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, in light of the
circumstances in which they were made, and will reimburse the Company, such directors and officers
and each person controlling the Company for reasonable legal and any other expenses reasonably
incurred in connection with investigating or defending any such claim, loss, damage, liability or
action as incurred, in each case to the extent, but only to the extent, that such untrue statement
or omission or allegation thereof is made in reliance upon and in conformity with written
information furnished to the Company by or on behalf of the Holder and stated to be specifically
for use in preparation of the Registration Statement, prospectus, any amendment or supplement
thereof, or other document incident to any such registration, qualification or compliance; provided
that the indemnity shall not apply to the extent that such claim, loss, damage or liability results
from the fact that a current copy of the prospectus was not made available to the person or entity
asserting the loss, liability, claim or damage at or prior to the time such furnishing is required
by the Securities Act and the Final Prospectus would have cured the defect giving rise to such
loss, claim, damage or liability. Notwithstanding the foregoing, (x) a Holder’s aggregate
liability pursuant to this subsection (b) and subsection (d) shall be limited to the net amount
received by the Holder from the sale of the Registrable Securities and (y) the Holder shall not be
liable to the Company for any consequential damages, including lost profits, solely with respect to
losses, claims, damages, liabilities or expenses to which the Company (or any officer, director or
controlling person as set forth above) may become subject (under the Securities Act or otherwise),
arising out of, or based upon, any failure to comply with the covenants and agreements concerning
its sale or other disposition of the Registrable Securities.

22.

 

          (c) Each party entitled to indemnification under this Section 7.7 (the “Indemnified Party”)
shall give notice to the party required to provide indemnification (the “Indemnifying Party”)
promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may
be sought, and shall permit the Indemnifying Party (at its expense) to assume the defense of any
such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party,
who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified
Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may
participate in such defense at such Indemnified Party’s expense, and provided further that the
failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Agreement, unless such failure is materially
prejudicial to the Indemnifying Party in defending such claim or litigation. An Indemnifying Party
shall not be liable for any settlement of an action or claim effected without its written consent
(which consent will not be unreasonably withheld). No Indemnifying Party, in its defense of any
such claim or litigation, shall, except with the consent of each Indemnified Party, consent to
entry of any judgment or enter into any settlement which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all
liability in respect to such claim or litigation.

          (d) If the indemnification provided for in this Section 7.7 is held by a court of competent
jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim,
damage or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such
Indemnified Party thereunder, shall contribute to the amount paid or payable by such Indemnified
Party as a result of such loss, liability, claim, damage or expense in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the
Indemnified Party on the other in connection with the statements or omissions which resulted in
such loss, liability, claim, damage or expense as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission to state a material fact relates to information supplied by the
Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission.

     7.8 (a) Each Holder agrees that, upon receipt of any notice from the Company of the happening
of any event requiring the preparation of a supplement or amendment to a prospectus relating to
Registrable Securities so that, as thereafter delivered to the Holders, such prospectus shall not
contain an untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading, each Holder will
forthwith discontinue disposition of Registrable Securities pursuant to the Registration Statement
and prospectus contemplated by Section 7.2 until its receipt of copies of the supplemented or
amended prospectus from the Company and, if so directed by the Company, each Holder shall deliver
to the Company all copies, other than permanent file copies then in such Holder’s possession, of
the prospectus covering such Registrable Securities current at the time of receipt of such notice.

23.

 

          (b) For not more than twenty (20) days in any 365-day period, the Company may delay the
disclosure of material non-public information concerning the Company, by suspending the offer and
sale of the Registrable Securities pursuant to the Registration Statement, the disclosure of which
information at the time is not, in the good faith opinion of the Company, in the best interests of
the Company (an “Allowed Delay”); provided, that the Company shall promptly (a) notify the Holders
in writing of the existence of (but in no event, without the prior written consent of a Holder,
shall the Company disclose to such Holder any of the facts or circumstances regarding) material
non-public information giving rise to an Allowed Delay, (b) advise the Holders in writing to cease
all offers and sales under the Registration Statement until the end of the Allowed Delay and (c)
use commercially reasonable efforts to terminate an Allowed Delay as promptly as reasonably
practicable. Each Holder hereby covenants that it will not sell any Registrable Securities pursuant
to the Registration Statement and the prospectus contained therein during the existence of an
Allowed Delay.

          (c) As a condition to the inclusion of its Registrable Securities, each Holder shall furnish
to the Company such information regarding such Holder and the distribution proposed by such Holder
as the Company may request in writing, including completing a Registration Statement Questionnaire
in the form provided by the Company, or as shall be required in connection with any registration
referred to in this Article 7.

          (d) Each Holder agrees not to take any action with respect to any distribution deemed to be
made pursuant to such Registration Statement which would constitute a violation of Regulation M
under the Exchange Act or any other applicable rule, regulation or law.

          (e) At the end of the Registration Period, the Holders shall discontinue sales of shares
pursuant to such Registration Statement upon receipt of notice from the Company of its intention to
remove from registration the shares covered by such Registration Statement which remain unsold, and
such Holders shall notify the Company of the number of shares registered which remain unsold
immediately upon receipt of such notice from the Company.

     7.9 With a view to making available to the Holders the benefits of certain rules and
regulations of the SEC which at any time permit the sale of the Registrable Securities to the
public without registration, so long as the Holders still own Registrable Securities, the Company
shall use its commercially reasonable efforts to:

          (a) make and keep public information available, as those terms are understood and defined in
Rule 144 under the Securities Act, at all times;

          (b) file with the SEC in a timely manner all reports and other documents required of the
Company under the Exchange Act; and

          (c) so long as a Holder owns any Registrable Securities, furnish to such Holder, upon any
reasonable request, a written statement by the Company as to its compliance with Rule 144 under the
Securities Act, and of the Exchange Act, a copy of the most recent annual or quarterly report of
the Company, and such other reports and documents of the Company as such Holder may reasonably
request in availing itself of any rule or regulation of the SEC allowing a Holder to sell any such
securities without registration.

24.

 

     7.10 The benefits granted to the Holders by the Company under Section 7.2 may be assigned in
full by a Holder in connection with a transfer by such Holder of its Registrable Securities,
provided, however, that (i) such transfer may otherwise be effected in accordance with applicable
securities laws; (ii) such Holder gives prior written notice to the Company at least 10 days prior
to the Filing Date; and (iii) such transferee agrees to comply with the terms and provisions of
this Agreement, and such transfer is otherwise in compliance with this Agreement. Except as
specifically permitted by this Section 7.10, the rights of a Holder with respect to Registrable
Securities as set out herein shall not be transferable to any other Person, and any attempted
transfer shall cause all rights of such Holder therein to be forfeited.

     7.11 With the written consent of the Company and the Holders holding at least a majority of
the Registrable Securities that are then outstanding, any provision of this Article 7 may be waived
(either generally or in a particular instance, either retroactively or prospectively and either for
a specified period of time or indefinitely) or amended. Upon the effectuation of each such waiver
or amendment, the Company shall promptly give written notice thereof to the Holders, if any, who
have not previously received notice thereof or consented thereto in writing.

     7.12 Without the consent of the Holders holding at least a majority of the Registrable
Securities, the Company shall not grant any additional registration rights unless such registration
rights are pari passu or subordinate to the registration rights provided to the Holders in this
Article 7; provided, however, that this Section 7.12 shall be of no force or effect from and after
the date that the Registration Statement filed in accordance with Section 7.2 hereof is declared
effective.

ARTICLE 8

RIGHT OF FIRST REFUSAL

     8.1 Subsequent Offerings. Subject to applicable securities laws, for a period beginning on
the date the Registration Statement to be filed under Section 7.2 hereof is declared effective by
the SEC and ending 180 days after such date (but under no circumstances after December 31, 2007)
(the “ROFR Period”) each Purchaser or its designated affiliate shall have a right of first refusal
to purchase its pro rata share of all Equity Securities (as defined below) that the Company may,
during such period, propose to sell and issue, other than the Equity Securities excluded by Section
8.5 hereof. Each Purchaser’s pro rata share is equal to the ratio of (a) the number of shares of
Common Stock (including all shares of Common Stock issuable or issued upon the exercise of
outstanding warrants, options or other rights to acquire Common Stock) of which such Purchaser is
deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total
number of shares of the Company’s Common Stock (including all shares of Common Stock issued or
issuable upon the exercise of any outstanding warrants, options or other rights to acquire Common
Stock) held by all of the Purchasers immediately prior to the issuance of the Equity Securities.
The term “Equity Securities” shall mean (i) any Common Stock or other security of the Company, (ii)
any security convertible into or exercisable or exchangeable for, with or without consideration,
any Common Stock or other security (including any option to purchase such a convertible security),
(iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock or
other security or (iv) any such warrant or right.

25.

 

     8.2 Exercise of Rights. If the Company proposes to issue any Equity Securities during the
ROFR Period, it shall give each Purchaser written notice of its intention, describing the Equity
Securities, the price and the terms and conditions upon which the Company proposes to issue the
same. Each Purchaser shall have five (5) business days from the receipt of such notice to agree to
purchase its pro rata share of the Equity Securities for the price and upon the terms and
conditions specified in the notice by giving written notice to the Company and stating therein the
quantity of Equity Securities to be purchased. Notwithstanding the foregoing, the Company shall
not be required to offer or sell such Equity Securities to any Purchaser who would cause the
Company to be in violation of applicable federal securities laws by virtue of such offer or sale.

     8.3 Issuance of Equity Securities to Other Persons. The Company shall have thirty (30) days
after delivery of the notice provided pursuant to Section 8.2 to sell the Equity Securities in
respect of which any Purchaser’s rights were not exercised, at a price and upon general terms and
conditions not more favorable to the purchasers thereof than specified in the Company’s notice to
the Purchasers pursuant to Section 8.2 hereof. If the Company has not sold such Equity Securities
within thirty (30) days of the notice provided pursuant to Section 8.2, the Company shall not
thereafter issue or sell any Equity Securities, without first offering such securities to the
Purchasers in the manner provided above.

     8.4 Assignment of Rights of First Refusal. The rights of first refusal of each Purchaser
under this Article 8 may be assigned to the same parties or their affiliates, subject to the same
restrictions as any transfer of registration rights pursuant to Section 7.10.

     8.5 Excluded Securities. The rights of first refusal established by this Article 8 shall have
no application to any of the following Equity Securities:

          (a) Equity Securities issued or to be issued after the date hereof to employees, officers or
directors of, or consultants or advisors to the Company or any subsidiary, pursuant to stock
purchase or stock option plans or other arrangements that are approved by the Company’s Board of
Directors;

          (b) Equity Securities outstanding as of the date of this Agreement, and Equity Securities
issued pursuant to any Equity Securities granted after the date of this Agreement, so long as the
rights of first refusal established by this Article 8 were complied with, waived, or were
inapplicable pursuant to any provision of this Section 8.5 with respect to the initial sale or
grant by the Company of such Equity Securities;

          (c) any Equity Securities issued for consideration other than cash pursuant to a merger,
consolidation, acquisition or similar business combination, provided that such transaction is not
primarily for capital raising purposes rather than strategic purposes;

          (d) any Equity Securities issued by the Company in connection with any stock dividends,
split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations,
reorganizations, liquidations, or the like;

          (e) any Equity Securities that are issued by the Company in a public offering pursuant to a
registration statement filed under the Securities Act; and

26.

 

           (f) any Equity Securities issued in connection with strategic transactions involving the
Company and other entities, including, without limitation (i) joint ventures, partnering,
manufacturing, marketing or distribution arrangements or (ii) licensing, intellectual property
transfer or development arrangements; provided that such transaction is not substantially for
equity financing purposes.

ARTICLE 9

INDEMNIFICATION

     In consideration of each Purchaser’s execution and delivery of this Agreement and its
acquisition of the Units hereunder, and in addition to all of the Company’s other obligations under
this Agreement, the Company will indemnify and hold harmless each Purchaser and each other holder
of the Units and all of their stockholders, officers, directors, employees and direct or indirect
Purchasers and any of the foregoing person’s agents or other representatives (including, without
limitation, those retained in connection with the transactions contemplated by this Agreement)
(collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection
therewith (regardless of whether any such Indemnitee is a party to the action for which
indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements
(the “Indemnified Liabilities”), incurred by an Indemnitee as a result of, or arising out of, or
relating to (a) any breach of any representation or warranty made by the Company in this Agreement
(b) any breach of any covenant, agreement or obligation of the Company contained in this Agreement
or (c) any cause of action, suit or claim brought against such Indemnitee and arising out of or
resulting from the execution, delivery, performance, breach or enforcement of this Agreement by the
Company. To the extent that the foregoing undertaking by the Company is unenforceable for any
reason, the Company will make the maximum contribution to the payment and satisfaction of each of
the Indemnified Liabilities that is permissible under applicable law.

ARTICLE 10

DEFINITIONS

     10.1 “Bylaws” has the meaning set forth in Section 3.3.

     10.2 “Certificate of Incorporation” has the meaning set forth in Section 3.3.

     10.3 “Closing” has the meaning set forth in Section 1.3.

     10.4 “Closing Date” has the meaning set forth in Section 1.3.

     10.5 “Common Stock” means the common stock, par value $.01 per share, of the Company.

     10.6 “Company” has the meaning set forth in the preamble to this Agreement.

     10.7 “Environmental Laws” has the meaning set forth in Section 3.10.

27.

 

     10.8 “Exchange Act” means the Securities Exchange Act of 1934, as amended.

     10.9 “Indemnitees” has the meaning set forth in Article 9.

     10.10 “Indemnified Liabilities” has the meaning set forth in Article 9.

     10.11 “Intellectual Property” has the meaning set forth in Section 3.8.

     10.12 “Material Adverse Effect” means a material adverse effect on (a) the business,
operations, assets or financial condition of the Company or (b) the ability of the Company to
perform its obligations pursuant to the transactions contemplated by this Agreement, other than the
following in and of themselves, either alone or in combination, none of which shall be taken into
account in determining whether there has been or will be a Material Adverse Effect: (w) any
adverse change, effect or occurrence attributable to the United States economy as a whole or the
Company’s industry, which change, effect or occurrence does not have a disproportionate effect on
the Company relative to the United States economy as a whole or the Company’s industry, as
applicable, (x) any act or threat of terrorism or war anywhere in the world, any armed hostilities
or terrorist activities anywhere in the world, any threat or escalation or armed hostilities or
terrorist activities anywhere in the world or any governmental or other response or reaction to any
of the foregoing, (y) any change in accounting requirements or principles or any change in
applicable laws, rules or regulations, or (z) any effect resulting from the announcement or
pendency of the Closing.

     10.13 “NASD” has the meaning set forth in Section 3.19.

     10.14 “Nasdaq” means the Nasdaq Global Market.

     10.15 “Offering” has the meaning set forth in Recital A.

     10.16 “Penalty” has the meaning set forth in Section 7.4.

     10.17 “Purchasers” mean the Purchasers whose names are set forth on the signature pages of
this Agreement, and their permitted transferees.

     10.18 “Purchase Price” has the meaning set forth in Section 1.1.

     10.19 “Registration Default” has the meaning set forth in Section 7.4.

     10.20 “Regulation D” means Regulation D as promulgated under by the SEC under the Securities
Act.

     10.21 “Rule 144” means Rule 144 promulgated under the Securities Act, or any successor rule.

     10.22 “SEC” means the United States Securities and Exchange Commission.

     10.23 “SEC Documents” has the meaning set forth in Section 3.6.

28.

 

     10.24 “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations thereunder, or any similar successor statute.

     10.25 “Shares” has the meaning set forth in Section 1.1.

     10.26 “Share Purchase Price” has the meaning set forth in Section 1.1.

     10.27 “to the Company’s knowledge” and variations thereon mean the actual knowledge of the
executive officers (as defined in Rule 405 under the Securities Act) of the Company, after due
inquiry.

     10.28 “Units” has the meaning set forth in Section 1.1.

     10.29 “Warrant Shares” has the meaning set forth in Section 3.4.

     10.30 “Warrants” has the meaning set forth in Section 1.1.

ARTICLE 11

GOVERNING LAW; MISCELLANEOUS

     11.1 Governing Law; Jurisdiction. This Agreement will be governed by and interpreted in
accordance with the laws of the State of California without regard to the principles of conflict of
laws. The parties hereto hereby submit to the exclusive jurisdiction of the United States federal
and state courts located in the County of Orange, State of California with respect to any dispute
arising under this Agreement or the transactions contemplated hereby or thereby.

     11.2 Counterparts; Signatures by Facsimile. This Agreement may be executed in two or more
counterparts, all of which are considered one and the same agreement and will become effective when
counterparts have been signed by each party and delivered to the other parties. This Agreement,
once executed by a party, may be delivered to the other parties hereto by facsimile transmission of
a copy of this Agreement bearing the signature of the party so delivering this Agreement.

     11.3 Headings. The headings of this Agreement are for convenience of reference only, are not
part of this Agreement and do not affect its interpretation.

     11.4 Severability. If any provision of this Agreement is invalid or unenforceable under any
applicable statute or rule of law, then such provision will be deemed modified in order to conform
with such statute or rule of law. Any provision hereof that may prove invalid or unenforceable
under any law will not affect the validity or enforceability of any other provision hereof.

     11.5 Entire Agreement; Amendments. This Agreement (including all schedules and exhibits
hereto) constitutes the entire agreement among the parties hereto with respect to the subject
matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other
than those set forth or referred to herein or therein. This Agreement supersedes all prior
agreements and understandings among the parties hereto with respect to the

29.

 

subject matter hereof. No provision of this Agreement may be waived or amended other than by
an instrument in writing signed by the party to be charged with enforcement.

     11.6 Notices. Any notices required or permitted to be given under the terms of this Agreement
must be sent by certified or registered mail (return receipt requested) or delivered personally or
by courier (including a recognized overnight delivery service) and will be effective five days
after being placed in the mail, if mailed by regular U.S. mail, or upon receipt, if delivered
personally, or by courier (including a recognized overnight delivery service), in each case
addressed to a party. The addresses for such communications are:

			
	     If to the Company:	 	IDM Pharma, Inc.

9 Parker, Suite 100

Irvine, CA 92618

Attn: Chief Executive Officer
	 
	     With a copy to:	 	Cooley Godward Kronish llp

4401 Eastgate Mall

San Diego, CA 92121

Attn: L. Kay Chandler, Esq.

     If to a Purchaser: To the address set forth immediately below such Purchaser’s name on the
signature pages hereto. Each party will provide written notice to the other parties of any change
in its address.

     11.7 Successors and Assigns. This Agreement is binding upon and inures to the benefit of the
parties and their successors and assigns. The Company will not assign this Agreement or any rights
or obligations hereunder without the prior written consent of the Purchasers, and no Purchaser may
assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Company.

     11.8 Third Party Beneficiaries. This Agreement is intended for the benefit of the parties
hereto, their respective permitted successors and assigns, and is not for the benefit of, nor may
any provision hereof be enforced by, any other person.

     11.9 Further Assurances. Each party will do and perform, or cause to be done and performed,
all such further acts and things, and will execute and deliver all other agreements, certificates,
instruments and documents, as another party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

     11.10 No Strict Construction. The language used in this Agreement is deemed to be the
language chosen by the parties to express their mutual intent, and no rules of strict construction
will be applied against any party.

     11.11 Equitable Relief. The Company recognizes that, if it fails to perform or discharge any
of its obligations under this Agreement, any remedy at law may prove to be

30.

 

inadequate relief to the Purchasers. The Company therefore agrees that the Purchasers are
entitled to seek temporary and permanent injunctive relief in any such case. Each Purchaser also
recognizes that, if it fails to perform or discharge any of its obligations under this Agreement,
any remedy at law may prove to be inadequate relief to the Company. Each Purchaser therefore
agrees that the Company is entitled to seek temporary and permanent injunctive relief in any such
case.

     11.12 Waiver of Conflict. Each party to this Agreement acknowledges that Cooley Godward
Kronish llp (“Cooley”), outside general counsel to the Company, has in the past performed
and is or may now or in the future represent one or more Purchasers or their affiliates in matters
unrelated to the Offering, including representation of such Purchasers or their affiliates in
matters of a similar nature to the Offering. The applicable rules of professional conduct require
that Cooley inform the parties hereunder of this representation and obtain their consent. Cooley
has served as outside general counsel to the Company and has negotiated the terms of the Offering
solely on behalf of the Company. It is the belief of Cooley that these terms and conditions
represent an arm’s length transaction between the Company and Purchasers. Each of the Company and
each Purchaser hereby (a) acknowledges that it has had an opportunity to ask for and have obtained
information relevant to such representation, including disclosure of the reasonably foreseeable
adverse consequences of such representation; (b) acknowledges that with respect to the Offering,
Cooley has represented solely the Company, and not any Purchaser or any stockholder, director or
employee of the Company or any Purchaser; and (c) gives its informed consent to Cooley’s
representation of the Company in the Offering.

     11.13 Independent Action. Nothing contained herein, and no action taken by any Purchaser,
shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or
any other kind of entity, or create a presumption that the Purchasers are in any way acting in
concert or as a group with respect to such obligations or the transactions contemplated hereby,
provided that such obligations or the transactions contemplated hereby may be modified, amended or
waived in accordance with the terms of this Agreement. Each Purchaser shall be entitled to
independently protect and enforce its rights, including without limitation the rights arising out
of this Agreement (provided, that such rights may be modified, amended or waived in accordance with
the terms of this Agreement), and it shall not be necessary for any other Purchaser to be joined as
an additional party in any proceeding for such purpose.

31.

 

     In Witness Whereof, the undersigned Purchasers and the Company have caused this
Agreement to be duly executed as of the date first above written.

	 	 	 	 	 
	 	IDM Pharma, Inc.

 	 
	 	By:  	/s/
Jean-Loup Romet-Lemonne	 
	 	 	Name:  	Jean-Loup Romet-Lemonne 	 
	 	 	Title:  	Chief Executive Officer
 	 
	 	 	Address:  	
9 Parker, Suite 100

Irvine, CA 92618

Facsimile: (949) 470-6439 	 
	 

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser 

Palo Alto Healthcare Master Fund, L.P.

 	 
	 	By:  	/s/  Mark Shamia
 	 
	 	 	Mark Shamia 	 
	 	 	Chief Operating Officer

Palo Alto Investors, LLC 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	470 University Avenue
	 

	 	 	 	Palo Alto, California 94301

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Micro Cap Partners, L.P.

 	 
	 	By:  	/s/  Mark Shamia
 	 
	 	 	Mark Shamia 	 
	 	 	Chief Operating Officer

Palo Alto Investors, LLC 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	470 University Avenue
	 

	 	 	 	Palo Alto, California 94301

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Palo Alto Fund II, L.P.

 	 
	 	By:  	/s/  Mark Shamia
 	 
	 	 	Mark Shamia 	 
	 	 	Chief Operating Officer

Palo Alto Investors, LLC 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	470 University Avenue
	 

	 	 	 	Palo Alto, California 94301

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Palo Alto Healthcare Fund II, L.P.

 	 
	 	By:  	/s/  Mark Shamia
 	 
	 	 	Mark Shamia 	 
	 	 	Chief Operating Officer

Palo Alto Investors, LLC 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	470 University Avenue
	 

	 	 	 	Palo Alto, California 94301

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Alta Embarcadero BioPharma Partners III, LLC

 	 
	 	By:  	/s/  Alix Marduel
 	 
	 	 	Alix Marduel 	 
	 	 	Manager 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	One Embarcadero Center Drive
	 

	 	 	 	Suite 3700
	 

	 	 	 	San Francisco, CA 94111 USA

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Alta BioPharma Partners III GmbH & Co.

Beteiligungs KG

 	 
	 	By:  	                                                   Alta BioPharma Management III, LLC
 	 
	 	 	 	 
	 	 	 	 
	 

	 	 	 	 	 
	 	 	 
	 	By:  	                      /s/  Alix Marduel
 	 
	 	 	Alix Marduel 	 
	 	 	Director 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	One Embarcadero Center Drive
	 

	 	 	 	Suite 3700
	 

	 	 	 	San Francisco, CA 94111 USA

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Alta BioPharma Partners III, L.P.

 	 
	 	By:  	                                                   Alta BioPharma Management III, LLC
 	 
	 	 	 	 
	 	 	 	 
	 

	 	 	 	 	 
	 	 	 
	 	By:  	                      /s/  Alix Marduel
 	 
	 	 	Alix Marduel 	 
	 	 	Director 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	One Embarcadero Center Drive
	 

	 	 	 	Suite 3700
	 

	 	 	 	San Francisco, CA 94111 USA

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

IDM Chase Partners (Alta Bio), LLC

 	 
	 	By:  	                                                   Alta/Chase BioPharma Management, LLC
 	 
	 	 	 	 
	 	 	 	 
	 

	 	 	 	 	 
	 	 	 
	 	By:  	                      /s/  Alix Marduel
 	 
	 	 	Alix Marduel 	 
	 	 	Member 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	One Embarcadero Center Drive
	 

	 	 	 	Suite 3700
	 

	 	 	 	San Francisco, CA 94111 USA

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Alta Embarcadero BioPharma Partners, LLC

 	 
	 	By:  	/s/  Alix Marduel
 	 
	 	 	Alix Marduel 	 
	 	 	Member 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	One Embarcadero Center Drive
	 

	 	 	 	Suite 3700
	 

	 	 	 	San Francisco, CA 94111 USA

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Alta BioPharma Partners, L.P.

 	 
	 	By:  	                                                   Alta BioPharma Management, LLC
 	 
	 	 	 	 
	 	 	 	 
	 

	 	 	 	 	 
	 	 	 
	 	By:  	                      /s/  Alix Marduel
 	 
	 	 	Alix Marduel 	 
	 	 	Managing Director 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	One Embarcadero Center Drive
	 

	 	 	 	Suite 3700
	 

	 	 	 	San Francisco, CA 94111 USA

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Vivo Ventures Fund V, L.P.

 	 
	 	By:  	/s/  Frank Kung
 	 
	 	 	Frank Kung 	 
	 	 	Managing Member of

Vivo Ventures V, LLC, its General Partner 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	Vivo Ventures
	 

	 	 	 	575 High Street, Suite 201
	 

	 	 	 	Palo Alto, California 94301

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

Vivo Ventures V Affiliates Fund, L.P.

 	 
	 	By:  	/s/  Frank Kung
 	 
	 	 	Frank Kung 	 
	 	 	Managing Member of

Vivo Ventures V, LLC, its General Partner 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	Vivo Ventures
	 

	 	 	 	575 High Street, Suite 201
	 

	 	 	 	Palo Alto, California 94301

Unit Purchase Agreement

Signature Page

 

 

	 	 	 	 	 
	 	Purchaser

BioAsia Crossover Fund, L.P.

 	 
	 	By:  	/s/  Frank Kung
 	 
	 	 	Frank Kung 	 
	 	 	Managing Member of

BioAsia Investments IV, LLC,
its General Partner 	 
	 

	 	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	Vivo Ventures
	 

	 	 	 	575 High Street, Suite 201
	 

	 	 	 	Palo Alto, California 94301

Unit Purchase Agreement

Signature Page

 

 

EXHIBIT A

SCHEDULE OF PURCHASERS

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Aggregate Purchase
	Purchaser	 	Shares	 	Warrants	 	Price
	Palo Alto Healthcare Master Fund, L.P.

470 University Ave

Palo Alto, CA 94301

Phone (650) 325-0772

Fax (650) 325-5028
	 	 	1,638,000	 	 	 	280,678	 	 	$	4,625,334.92	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Micro Cap Partners, L.P.

470 University Ave

Palo Alto, CA 94301

Phone (650) 325-0772

Fax (650) 325-5028
	 	 	1,071,000	 	 	 	183,520	 	 	$	3,024,257.44	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Palo Alto Fund II, L.P.

470 University Ave

Palo Alto, CA 94301

Phone (650) 325-0772

Fax (650) 325-5028
	 	 	252,000	 	 	 	43,181	 	 	$	711,589.98	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Palo Alto Healthcare Fund II, L.P.

470 University Ave

Palo Alto, CA 94301

Phone (650) 325-0772

Fax (650) 325-5028
	 	 	189,000	 	 	 	32,386	 	 	$	533,692.49	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Alta BioPharma Partners, L.P.

One Embarcadero Center

37th Floor

San Francisco, CA 94111

Phone (415) 362-4022

Fax (415) 362-6178
	 	 	220,126	 	 	 	37,719	 	 	$	621,585.14	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	IDM Chase Partners (AltaBio), LLC

One Embarcadero Center

37th Floor

San Francisco, CA 94111

Phone (415) 362-4022

Fax (415) 362-6178
	 	 	125,713	 	 	 	21,541	 	 	$	354,984.56	 

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Aggregate Purchase
	Purchaser	 	Shares	 	Warrants	 	Price
	Alta Embarcadero BioPharma Partners, LLC

One Embarcadero Center

37th Floor

San Francisco, CA 94111

Phone (415) 362-4022

Fax (415) 362-6178
	 	 	8,297	 	 	 	1,421	 	 	$	23,428.80	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Alta BioPharma Partners III, L.P.

One Embarcadero Center

37th Floor

San Francisco, CA 94111

Phone (415) 362-4022

Fax (415) 362-6178

	 	 	648,718	 	 	 	111,160	 	 	$	1,831,830.28	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Alta BioPharma Partners III GmbH & Co.

Beteiligungs KG

One Embarcadero Center

37th Floor

San Francisco, CA 94111

Phone (415) 362-4022

Fax (415) 362-6178
	 	 	43,567	 	 	 	7,465	 	 	$	123,023.17	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Alta Embarcadero BioPharma Partners
III, LLC

One Embarcadero Center

37th Floor

San Francisco, CA 94111

Phone (415) 362-4022

Fax (415) 362-6178
	 	 	15,987	 	 	 	2,739	 	 	$	45,143.60	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Vivo Ventures Fund V, L.P.

575 High Street, Suite 201

Palo Alto, CA 94301

Phone (650) 688-0818

Fax (650) 688-0815
	 	 	318,612	 	 	 	54,595	 	 	$	899,686.93	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Vivo Ventures V Affiliates Fund, L.P.

575 High Street, Suite 201

Palo Alto, CA 94301

Phone (650) 688-0818

Fax (650) 688-0815
	 	 	3,739	 	 	 	640	 	 	$	10,558.06	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	BioAsia Crossover Fund, L.P.

575 High Street, Suite 201

Palo Alto, CA 94301

Phone (650) 688-0818

Fax (650) 688-0815
	 	 	32,236	 	 	 	5,523	 	 	$	91,027.03	 
	Total
	 	 	4,566,995	 	 	 	782,568	 	 	$	12,896,142.40	 

 

 

EXHIBIT B

WARRANT

 

 

EXHIBIT C

BANK OF AMERICA

WIRE TRANSFER INSTRUCTIONS

The following information is provided to assist clients in routing wire transfers TO Bank
of America in the most expeditious manner.

Bank of America Contact: Lolita Tagulao PH: (800) 545-0232 or (510) 873-5832 FX: (510) 873-5805

DOMESTIC WIRE TRANSFER:

Bank of America

ABA# 026009593

Acct# 86666-10507

FFC: IDM Pharma, Inc., Acct # 72-40-400-7569840

INTERNATIONAL WIRE TRANSFER:

Instruct the paying financial institution to advise their U.S. correspondent to pay as follows:

Bank of America

ABA# 026009593

Swift Code: BOFAUS3N

Acct# 86666-10507

FFC: IDM Pharma, Inc., Acct # 72-40-400-7569840

 

 

EXHIBIT D

INVESTOR QUESTIONNAIRE AND

INSTRUCTION SHEET FOR PURCHASER

Complete the following items in connection with the Unit Purchase Agreement:

	 	1.	 	Provide the information regarding the Purchaser requested on the signature
page. The Unit Purchase Agreement must be executed by an individual authorized to bind
the Purchaser.
	 
	 	2.	 	Exhibit D-1 — Stock Certificate Questionnaire:

Provide the information requested by the Stock Certificate Questionnaire.

	 	3.	 	Exhibit D-2 — Registration Statement Questionnaire:

Provide the information requested by the Registration Statement Questionnaire.

	 	4.	 	Exhibit D-3 — Purchaser Certificate:

Provide the information requested by the Certificate for Individual Purchasers or
the Certificate for Corporate, Partnership, Trust, Foundation and Joint Purchasers,
as applicable.

	 	5.	 	Return the signed Unit Purchase Agreement to:

Deborah R. Cravets

Cooley Godward Kronish llp

4401 Eastgate Mall

San Diego, California 92121

Fax: 858.550.6420

1.

 

Exhibit D-1

IDM PHARMA, INC.

STOCK CERTIFICATE QUESTIONNAIRE

In connection with the stock certificates to be delivered pursuant to Section 1.2 of the
Agreement, please provide us with the following information:

	 	 	 	 	 
	1.

	 	The exact name that the Shares are to be registered in (this is the
name that will appear on the stock certificate(s)). You may use a
nominee name if appropriate:
	 	 

	 
	 	 	 	 
	2.

	 	The relationship between the Purchaser of the Shares and the
registered holder listed in response to item 1 above:
	 	 

	 
	 	 	 	 
	3.

	 	The mailing address of the registered holder listed in response to
item 1 above:
	 	 

	 
	 	 	 	 
	 

	 	 	 	 

	 
	 	 	 	 
	 

	 	 	 	 

	 
	 	 	 	 
	 

	 	 	 	 

	 
	 	 	 	 
	 

	 	 	 	 

	 
	 	 	 	 
	4.

	 	The Tax Identification Number of the registered holder listed in
response to item 1 above:
	 	 

1

 

Exhibit D-2

IDM
PHARMA, INC.

REGISTRATION STATEMENT QUESTIONNAIRE

     In connection with the preparation of the Registration Statement, please provide us with
the following information regarding the Purchaser.

A. General Information

	 	1.	 	Please state your name or your organization’s name exactly as it should appear
in the Registration Statement:                                                             
	 
	 	2.	 	Have you or your organization had any position, office or other material
relationship within the past three years with the Company or its affiliates?

o Yes     o No

     If yes, please indicate the nature of any such relationships below:

      

      

B.  Securities Holdings

     Please fill in all blanks in the following questions related to your beneficial ownership of
the Company’s capital stock. Generally, the term “beneficial ownership” refers to any direct or
indirect interest in the securities which entitles you to any of the rights or benefits of
ownership, even though you may not be the holder of record of the securities. For example,
securities held in “street name” over which you exercise voting or investment power would be
considered beneficially owned by you. Other examples of indirect ownership include ownership by a
partnership in which you are a partner or by an estate or trust of which you or any member of your
immediate family is a beneficiary. Ownership of securities held in the names of your spouse, minor
children or other relatives who live in the same household may be attributed to you.

     Please note: If you have any reason to believe that any interest in securities of the
Company which you may have, however remote, is a beneficial interest, please describe such
interest. For purposes of responding to this questionnaire, it is preferable to err on the side of
inclusion rather than exclusion. Where the SEC’s interpretation of beneficial ownership would
require disclosure of your interest or possible interest in certain securities of the Company, and
you believe that you do not actually possess the attributes of beneficial ownership, an appropriate
response is to disclose the interest and at the same time disclaim beneficial ownership of the
securities.

1

 

	 	1.	 	As of February 16, 2006, I owned outright (including shares
registered in my name individually or jointly with others, shares held in the name of a
bank, broker, nominee, depository or in “street name” for my account), the following
number of shares of the Company’s capital stock:                                         .
	 
	 	2.	 	In addition to the number of shares I own outright as indicated by my answer to
question B(1), as of February 16, 2006, I had or shared voting power
or investment power, directly or indirectly, through a contract, arrangement,
understanding, relationship or otherwise, over the following number of shares of the
Company’s capital stock:                                         .

     If the answer to this question B(2) was not “zero,” please complete the following: with whom
shared; and the nature of the relationship and any underlying voting trust agreement, investment
arrangement or the like:

Shared Voting Power:

	 	 	 	 	 
	Number of Shares
	 	With Whom Shared
	 	Nature of Relationship
	 

Shared Investment Power:

	 	 	 	 	 
	Number of Shares
	 	With Whom Shared
	 	Nature of Relationship
	 

	 	3.	 	As of April 17, 2006, I will have the right to acquire                       shares
of the Company’s capital stock pursuant to outstanding stock options issued
under the Company’s stock option plans and         
             shares pursuant to the exercise of
outstanding warrants (none, indicated by “0” above).

	 	 	 
	 Options and Warrants
	Class
	 	Number of Shares

2

 

	 	4.	 	Please identify the natural person or persons who have voting and/or investment
control over the Company’s securities that you own, and state whether such person(s)
disclaims beneficial ownership of the securities. For example, if you are a general
partnership, please identify the general partners in the partnership.

 

 

 

 

 

 

3

 

C. NASD Questions

     1. Are you (i) a “member”1 of the National Association of Securities Dealers,
Inc. (the “NASD”), (ii) an “affiliate”2 of a member of the NASD, (iii) a “person
associated with a member” or an “associated person of a member”3 of the NASD or (iv) an
immediate family member4 of any of the foregoing persons? If yes, please identify the
member and describe such relationship (whether direct or indirect), and please respond to Question
Number 2 below; if no, please proceed directly to Question Number 3.

Yes                          No                     

Description:

 

			
	1	 	NASD defines a “member” as
any broker or dealer admitted to membership in the NASD, or any officer or
partner or branch manager of such a member, or any person occupying a similar
status or performing a similar function for such a member.
	 
	2	 	The term “affiliate” means a
person that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is in common control with, the person
specified. Persons who have acted or are acting on behalf of or for the
benefit of a person include, but are not necessarily limited to, directors,
officers, employees, agents, consultants and sales representatives. The
following should apply for purposes of the foregoing:

 				
	 
	 	(i)	 	a person should be presumed to control a Member if the person
beneficially owns 10 percent or more the outstanding voting securities of a
Member which is a corporation, or beneficially owns a partnership interest in
10 percent or more of the distributable profits or losses of a Member which is
a partnership;

	 
	 	(ii)	 	a Member should be presumed to control a person if the Member and
Persons Associated With a Member beneficially own 10 percent or more of the
outstanding voting securities of a person which is a corporation, or
beneficially own a partnership interest in 10 percent or more of the
distributable profits or losses of a person which is a partnership;
	 
	 	(iii)	 	a person should be presumed to be under common control with a Member
if:

				
	 
	 	(1)	 	the same person controls both the Member and another person by
beneficially owning 10 percent or more of the outstanding voting
securities of a Member or person which is a corporation, or by
beneficially owning a partnership interest in 10 percent or more of the
distributable profits or losses of a Member or person which is a
partnership; or
	 
	 	(2)	 	a person having the power to direct or cause the direction of the
management or policies of the Member or such person also has the power to
direct or cause the direction of the management or policies of the other entity
in question.

 

    			
	 
	3	 	The NASD defines a “person
associated with a member” or an “associated person of a
member” as being every sole proprietor, partner, equity owner, officer,
director or branch manager of any member, or any natural person occupying a
similar status or performing similar functions, or any natural person engaged
in the investment banking or securities business who directly or indirectly
controls or is controlled by such member (for example, any employee), whether
or not any such person is registered or exempt from registration with the NASD.
	 
	4	 	Immediate family includes parents,
mother-in-law, father-in-law, husband or wife, brother or sister,
brother-in-law or sister-in-law, son-in-law or daughter-in-law, and children,
or any other person who is supported, directly or indirectly, to a material
extent, by a person associated with a member of the NASD or any other
broker/dealer.

4

 

     2. If you answered “yes” to Question Number 1, please furnish any information as to whether
any such member intends to participate in any capacity in the public offering, including the
details of such participation:

Description:

     3. Are you or have you been an “underwriter or related person”5 or a person
associated with an underwriter or related person, including, without limitation, with respect to
the proposed public offering? If yes, please identify the underwriter or related person and
describe such relationship (whether direct or indirect).

Yes                          No                     

Description:

     4. If known, please describe in detail any underwriting compensations, arrangements or
dealings entered into during the previous twelve months, or proposed to be consummated in the next
twelve months, between (i) any underwriter or related person, member of the NASD, affiliate of a
member of the NASD, person associated with a member or associated person of a member of the NASD or
any immediate family member thereof, on the one hand, and (ii) the Company, or any director,
officer or stockholder thereof, on the other hand, which provides for the receipt of any item of
value and/or the transfer of any warrants, options or other securities from the Company to any such
person (other than the information relating to the arrangements with any investment firm or
underwriting organization which may participate in the proposed public offering).

Description:

     5. Have you purchased the securities in the ordinary course of business ?

Yes                          No                     

 

			
	5	 	The term “underwriter or related
person” includes underwriters, underwriters’ counsel, financial
consultants and advisors, finders, members of the selling or distribution
group, and any and all other persons associated with or related to any of such
persons, including members of the immediate family of such persons.

5

 

The answers to the foregoing questions are correctly stated to the best of my information and
belief. I shall advise Deborah R. Cravets at 858.550.6417 promptly of any changes in the foregoing
information prior to the effectiveness of the Registration Statement.

	 	 	 	 	 
	 
	 	
(Print name of Holder)

	 
	 	
(Signature)

	 

	 	By:  	 	 
	 	 	(Name and title of signatory, if stockholder is an entity) 	 
	 
	 	
(Date)
	 

6

 

Exhibit D-3

IDM PHARMA, INC.

CERTIFICATE FOR INDIVIDUAL PURCHASERS

     If the investor is an individual Purchaser (or married couple) the Purchaser must
complete, date and sign this Certificate.

Certificate

     I certify that the representations and responses below are true and accurate:

     In order for the Company to offer and sell the Units in conformance with state and federal
securities laws, the following information must be obtained regarding your investor status. Please
initial each category applicable to you as an investor in the Company.

           (1) A natural person whose net worth1, either individually or jointly with
such person’s spouse exceeds $1,000,000;

           (2) A natural person who had an income2 in excess of $200,000, or joint
income with the person’s spouse in excess of $300,000, in 2005 and 2006, and reasonably expects to
have individual income reaching the same level in 2007;

           (3) An executive officer or director of the Company.

	 	 	 	 	 	 	 	 
	 

	 	
	 	 
	 	 
	Date: 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	 	 	Name(s) of Purchaser
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	 	 	Signature
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	 	 	Signature

 

			
	1	 	For purposes of this Certificate,
“net worth” means the excess of total assets at fair market value
over total liabilities, except that the principal residence owned by a natural
person shall be valued either (a) at cost, including the cost of improvements,
net of current encumbrances upon the property, or (b) at the appraised value of
the residence as determined upon a written appraisal used by an institutional
lender making a loan to the individual secured by the property, including the
cost of subsequent improvements, net of current encumbrances upon the property.
As used in the preceding sentence, “institutional lender” means a
bank, savings and loan company, industrial loan company, credit union or
personal property broker or a company whose principal business is as a lender
of loans secured by real property and which has such loans receivable in the
amount of $2,000,000 or more.
	 
	2	 	For purposes of this Certificate,
“income” means adjusted gross income, as reported for federal
income tax purposes, increased by the following amounts: (a) the amount of any
tax exempt interest income received, (b) the amount of losses claimed as a
limited partner in a limited partnership, (c) any deduction claimed for
depletion, (d) amounts contributed to an IRA or Keogh retirement plan, (e)
alimony paid, and (f) any amounts by which income from long-term capital gains
has been reduced in arriving at adjusted gross income pursuant to the
provisions of Section 1202 of the Internal Revenue Code.

1.

 

Exhibit D-3

IDM PHARMA, INC.

CERTIFICATE FOR CORPORATE, PARTNERSHIP,

TRUST, FOUNDATION, AND JOINT PURCHASERS

     If the investor is a corporation, partnership, trust, pension plan, foundation, joint
purchaser (other than a married couple) or other entity, an authorized officer, partner, or trustee
must complete, date and sign this Certificate.

Certificate

     The undersigned certifies that the representations and responses below are true and accurate:

     (a) The investor has been duly formed and is validly existing and has full power and authority
to invest in the Company. The person signing on behalf of the undersigned has the authority to
execute and deliver the Unit Purchase Agreement on behalf of the Purchaser and to take other
actions with respect thereto.

     (b) Indicate the form of entity of the undersigned:

	 	 	 	 	 
	 

	 	o
	 	Limited Partnership
	 
	 	 	 	 
	 

	 	o
	 	General Partnership
	 
	 	 	 	 
	 

	 	o
	 	Corporation
	 
	 	 	 	 
	 

	 	o
	 	Revocable Trust (identify each grantor and indicate under what circumstances
the trust is revocable by the grantor:  
	 
	 	 	 	 
	 

	 	 	 	 

 

 

 

(Continue on a separate piece of paper, if necessary.)
	 
	 	 	 	 
	 

	 	o
	 	Other Type of Trust (indicate type of trust and, for trusts other than
pension trusts, name the grantors and beneficiaries:
	 
	 	 	 	 
	 

	 	 	 	 

 

 

 

(Continue on a separate piece of paper, if necessary.)
	 
	 	 	 	 
	 

	 	o
	 	Other form of organization (indicate form of organization (                    ).

     (c)
Indicate the approximate date the undersigned entity was
formed:                     .

1.

 

     (d) In order for the Company to offer and sell the Units in conformance with state and federal
securities laws, the following information must be obtained regarding your investor status. Please
initial each category applicable to you as an investor in the Company.

           (1) A bank as defined in Section 3(a)(2) of the Securities Act, or any savings
and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities
Act whether acting in its individual or fiduciary capacity;

           (2) A broker or dealer registered pursuant to Section 15 of the Securities
Exchange Act of 1934;

           (3) An insurance company as defined in Section 2(13) of the Securities Act;

           (4) An investment company registered under the Investment Company Act of 1940
or a business development company as defined in Section 2(a)(48) of that Act;

           (5) A Small Business Investment Company licensed by the U.S. Small Business
Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;

           (6) A plan established and maintained by a state, its political subdivisions,
or any agency or instrumentality of a state or its political subdivisions, for the benefit
of its employees, if such plan has total assets in excess of $5,000,000;

           (7) An employee benefit plan within the meaning of the Employee Retirement
Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as
defined in Section 3(21) of such act, which is either a bank, savings and loan association,
insurance company, or registered investment adviser, or if the employee benefit plan has
total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions
made solely by persons that are accredited investors;

           (8) A private business development company as defined in Section 202(a)(22) of
the Investment Advisers Act of 1940;

           (9) An organization described in Section 501(c)(3) of the Internal Revenue
Code, a corporation, Massachusetts or similar business trust, or partnership, not formed for
the specific purpose of acquiring the Units, with total assets in excess of $5,000,000;

           (10) A trust, with total assets in excess of $5,000,000, not formed for the
specific purpose of acquiring the Units, whose purchase is directed by a sophisticated
person who has such knowledge and experience in financial and business matters that such
person is capable of evaluating the merits and risks of investing in the Company;

           (11) An entity in which all of the equity owners qualify under any of the above
subparagraphs. If the undersigned belongs to this investor category only, list

2.

 

the equity owners of the undersigned, and the investor category which each such equity
owner satisfies:

 

 

 

 

(Continue on a separate piece of paper, if necessary.)

 

	 	 	 	 	 
	Dated:

	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	 
	Name of investor	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	 
	Signature and title of authorized

officer, partner or trustee	 	 

3.

 

EXHIBIT E

FORM OF LEGAL OPINIONExhibit 4.2

 

EXHIBIT 4.2

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN
OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

IDM PHARMA, INC.

WARRANT TO PURCHASE COMMON STOCK

	 	 	 
	No. CW-___

	 	February 20, 2007

Void
After February 20, 2012

     This Certifies That, for value received, ___, with its
principal office at ___, or assigns (the “Holder”), is entitled to subscribe
for and purchase at the Exercise Price (defined below) from IDM Pharma, Inc., a Delaware
corporation, with its principal office at 9 Parker, Suite 100, Irvine, CA 92618 (the “Company”) up
to ___ shares of the Common Stock of the Company (the “Common Stock”). This Warrant is
being issued pursuant to the terms of the Unit Purchase Agreement, dated February 20, 2007 by and
among the Company and the Purchasers (as defined therein) (the “Purchase Agreement”).

     1. Definitions. As used herein, the following terms shall have the following
respective meanings:

          (a) “Change In Control” shall mean the occurrence, in a single transaction or in a series of
related transactions, of any one or more of the following events:

               (i) there is consummated a merger, consolidation or similar transaction involving (directly or
indirectly) the Company;

               (ii) there is consummated a sale, lease, exclusive license or other disposition of all or
substantially all of the consolidated assets of the Company and its subsidiaries; or

               (iii) any tender offer or exchange offer (whether by the Company or another person) completed
pursuant to which holders of Common Stock tender or exchange their shares for other securities,
cash or property; or

               (iv) the Company effects any reclassification of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property;

1.

 

          (b) “Exercise Period” shall mean the period commencing with the date hereof and ending on the
date five years from the date hereof, unless sooner terminated as provided in Section 7 below and
subject to extension pursuant to Section 8 below.

          (c) “Exercise Price” shall mean $3.243 per Exercise Share, subject to adjustment pursuant to
Section 5 below.

          (d) “Exercise Shares” shall mean the shares of Common Stock issuable upon exercise of this
Warrant, subject to adjustment pursuant to the terms herein, including but not limited to
adjustment pursuant to Section 5 below.

          (e)
“Own,” “Ownership.” A person or entity shall be deemed to “Own” or to have acquired
“Ownership” of securities if such person or entity, directly or indirectly, through any contract,
arrangement, understanding, relationship or otherwise, has or shares voting power, which includes
the power to vote or to direct the voting, with respect to such securities.

     2. Exercise of Warrant. 

          2.1 Exercise of Warrant. The rights represented by this Warrant may be exercised in whole or
in part at any time during the Exercise Period, by delivery of the following to the Company at its
address set forth above (or at such other address as it may designate by notice in writing to the
Holder):

          (a) An executed Notice of Exercise in the form attached hereto;

          (b) Payment of the Exercise Price either (i) in cash or by check, (ii) by cancellation of
indebtedness or (iii) pursuant to the net exercise provisions set forth in Section 2.2; and

          (c) This Warrant.

     Upon the exercise of the rights represented by this Warrant, a certificate or certificates for
the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with
the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a
reasonable time after the rights represented by this Warrant shall have been so exercised.

     The person in whose name any certificate or certificates for Exercise Shares are to be issued
upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on
the date on which this Warrant was surrendered and payment of the Exercise Price was made,
irrespective of the date of delivery of such certificate or certificates, except that, if the date
of such surrender and payment is a date when the stock transfer books of the Company are closed,
such person shall be deemed to have become the holder of such shares at the close of business on
the next succeeding date on which the stock transfer books are open.

          2.2 Net Exercise. Notwithstanding any provisions herein to the contrary, if the Fair Market
Value (as defined below) of one share of Common Stock is greater than the Exercise Price (at the
date of calculation as set forth below), in lieu of exercising this Warrant by

2.

 

payment of cash, check or cancellation of indebtedness the Holder may elect to receive shares
equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by
surrender of this Warrant at the principal office of the Company together with the properly
endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of shares
of Common Stock computed using the following formula:

	 	 	 	 	 	 	 	 	 
	 

	 	X
	 	=
	 	Y (A-B)
	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	A	 	 

	 	 	 	 	 	 	 
	Where

	 	X
	 	=
	 	the number of shares of Common Stock to be issued to the Holder
	 
	 	 	 	 	 	 
	 

	 	Y
	 	=
	 	the number of shares of Common Stock purchasable under the
	 

	 	 	 	 	 	Warrant or, if only a portion of the Warrant is being exercised, the portion of
	 

	 	 	 	 	 	the Warrant being canceled (at the date of such calculation)
	 
	 	 	 	 	 	 
	 

	 	A
	 	=
	 	the Fair Market Value (as defined below) of one share of
	 

	 	 	 	 	 	Common Stock (at the date of such calculation)
	 
	 	 	 	 	 	 
	 

	 	B
	 	=
	 	Exercise Price (as adjusted to the date of such calculation)

For purposes of this Warrant, the “Fair Market Value” of one share of Common Stock shall be the
closing bid price of the Common Stock as reported on The Nasdaq Global Market, or the last reported
sales price for the Common Stock if it is primarily traded on any other national securities
exchange or over-the-counter market, on the trading day immediately preceding the date of exercise.

          2.3 Limitations on Exercise. The Company shall not effect the exercise of this Warrant, and
the Holder shall not have the right to exercise this Warrant, to the extent that after giving
effect to such exercise, such Holder (together with such Holder’s affiliates) would beneficially
own in excess of 19.99% (the “Maximum Percentage”) of the number of shares of Common Stock
outstanding immediately after giving effect to such exercise. For purposes of the foregoing
sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its
affiliates shall include the number of shares of Common Stock issuable upon exercise of this
Warrant with respect to which the determination of such sentence is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining,
unexercised portion of this Warrant beneficially owned by such Holder and its affiliates and (ii)
exercise or conversion of the unexercised or unconverted portion of any other securities of the
Company beneficially owned by such Holder and its affiliates (including, without limitation, any
convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion
or exercise analogous to the limitation contained herein. Except as set forth in the preceding
sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Securities Exchange Act of 1934, as amended. For purposes of this
Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on
the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form
10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange
Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any
other notice by the

3.

 

Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
For any reason at any time, upon the written request of the Holder, the Company shall within one
business day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including the
Warrants, by the Holder and its affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. Neither the Holder nor the Company may waive application of
this Section 2.3.

     3. Covenants of the Company.

          3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise
Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon
issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes,
liens and charges with respect to the issuance thereof. The Company further covenants and agrees
that the Company will at all times during the Exercise Period, have authorized and reserved, free
from preemptive rights, a sufficient number of shares of its Common Stock to provide for the
exercise of the rights represented by this Warrant. If at any time during the Exercise Period the
number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise
of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel,
be necessary to increase its authorized but unissued shares of Common Stock to such number of
shares as shall be sufficient for such purposes.

          3.2 No Impairment. Except and to the extent as waived or consented to by the Holder, the
Company will not, by amendment of its Amended and Restated Certificate of Incorporation, as
amended, or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms to be observed or performed hereunder by the Company, but will at
all times in good faith assist in the carrying out of all the provisions of this Warrant and in the
taking of all such action as may be necessary or appropriate in order to protect the exercise
rights of the Holder against impairment.

          3.3 Notices of Events. In the event of any taking by the Company of a record of the holders
of any class of securities for the purpose of determining the holders thereof who are entitled to
receive any dividend (other than a cash dividend which is the same as cash dividends paid in
previous quarters) or other distribution, the Company shall mail to the Holder, at least ten days
prior to the applicable record date or effective date of such event, a notice describing the
material terms and conditions of such transaction (but only to the extent such disclosure would not
result in the dissemination of material, non-public information to the Holder). The Company shall
deliver prompt notice, but in no event later than four (4) business days, of (i) the Company’s
entering into any agreement contemplating or soliciting stockholder approval for a Change in
Control or (ii) any event requiring adjustment to the Exercise Price of the Warrant, stating the
adjusted Exercise Price and the adjusted number of Exercise Shares resulting from such event and
setting forth in reasonable detail the method of calculation and the facts upon which such
calculation is based.

4.

 

           3.4 Registration Rights. The Company agrees that the Exercise Shares shall be subject to the
registration rights set forth in Article 7 of the Purchase Agreement.

     4. Representations of Holder.

          4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it
is acquiring the Warrant and the Exercise Shares solely for its account for investment and not with
a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The
Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise
Shares the Holder is acquiring is being acquired for, and will be held for, its account only.

          4.2 Securities Are Not Registered.

               (a) The Holder understands that the Warrant and the Exercise Shares have not been registered
under the Securities Act of 1933, as amended (the “Act”) on the basis that no distribution or
public offering of the stock of the Company is to be effected. The Holder realizes that the basis
for the exemption may not be present if, notwithstanding its representations, the Holder has a
present intention of acquiring the securities for a fixed or determinable period in the future,
selling (in connection with a distribution or otherwise), granting any participation in, or
otherwise distributing the securities. The Holder has no such present intention.

               (b) The Holder recognizes that the Warrant and the Exercise Shares must be held indefinitely
unless they are subsequently registered under the Act or an exemption from such registration is
available. The Holder recognizes that the Company has no obligation to register the Warrant or the
Exercise Shares (except to the extent set forth in the Purchase Agreement), or ever comply with any
exemption from such registration.

               (c) The Holder is aware that neither the Warrant nor the Exercise Shares may be sold pursuant
to Rule 144 adopted under the Act unless certain conditions are met, including, among other things,
the existence of a public market for the Exercise Shares, the availability of certain current
public information about the Company, the resale following the required holding period under Rule
144 and the number of Exercise Shares being sold during any three month period not exceeding
specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have
not been satisfied.

          4.3 Disposition of Warrant and Exercise Shares.

               (a) The Holder agrees not to make any disposition of all or any part of the Warrant in any
event unless and until:

                    (i) The Company shall have received a letter secured by the Holder from the Securities and
Exchange Commission stating that no action will be recommended to the Commission with respect to
the proposed disposition;

5.

 

                    (ii) There is then in effect a registration statement under the Act covering such proposed
disposition and such disposition is made in accordance with said registration statement; or

                    (iii) The Holder shall have notified the Company of the proposed disposition and shall have
furnished the Company with a detailed statement of the circumstances surrounding the proposed
disposition, and if reasonably requested by the Company, the Holder shall have furnished the
Company with an opinion of counsel, in customary form and reasonably satisfactory to the Company,
for the Holder to the effect that such disposition will not require registration of such Warrant
under the Act or any applicable state securities laws.

               (b) Except as provided in the Purchase Agreement, the Holder understands and agrees that all
certificates evidencing the Exercise Shares to be issued to the Holder may bear a legend in
substantially the following form:

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE
SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.

     5. Adjustment of Exercise Price. 

          5.1 Stock Dividends, Split-ups, Recapitalizations, Etc.

               (a) In the event of changes in the outstanding Common Stock of the Company by reason of stock
dividends, split-ups, combinations, distributions in shares of Common Stock, exchanges of shares,
separations, liquidations, or the like, the number and class of shares available under the Warrant
in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the
Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of
shares as the Holder would have owned had the Warrant been exercised prior to the event and had the
Holder continued to hold such shares until after the event requiring adjustment; provided, however,
that such adjustment shall not be made with respect to any Cash Transaction (as defined in Section
7 below). The form of this Warrant need not be changed because of any adjustment in the number of
Exercise Shares subject to this Warrant.

               (b) Notwithstanding the foregoing, if any reorganization, reclassification of the capital
stock of the Company, consolidation or merger of the Company with another corporation in which the
Company is not the survivor, or sale, transfer or other disposition of all or substantially all of
the Company’s assets to another corporation shall be effected, then, as a condition of such
reorganization, reclassification, consolidation, merger, sale, transfer or other disposition,
lawful and adequate provision shall be made whereby each Holder shall thereafter have the right to
purchase and receive upon the basis and upon the terms and

6.

 

conditions herein specified and in lieu of the Exercise Shares immediately theretofore
issuable upon exercise of the Warrant, such shares of stock, securities or assets as would have
been issuable or payable with respect to or in exchange for a number of Exercise Shares equal to
the number of Exercise Shares immediately theretofore issuable upon exercise of the Warrant, had
such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition
not taken place, and in any such case appropriate provision shall be made with respect to the
rights and interests of each Holder to the end that the provisions hereof (including, without
limitation, provision for adjustment of the Exercise Price) shall thereafter be applicable, as
nearly equivalent as may be practicable in relation to any shares of stock, securities or assets
thereafter deliverable upon the exercise hereof. The Company shall not effect any such
consolidation, merger, sale, transfer or other disposition unless prior to or simultaneously with
the consummation thereof the successor corporation (if other than the Company) resulting from such
consolidation or merger, or the corporation purchasing or otherwise acquiring such assets or other
appropriate corporation or entity shall assume the obligation to deliver to the Holder, at the last
address of the Holder appearing on the books of the Company, such shares of stock, securities or
assets as, in accordance with the foregoing provisions, the Holder may be entitled to purchase, and
the other obligations under this Warrant. The provisions of this paragraph (b) shall similarly
apply to successive reorganizations, reclassifications, consolidations, mergers, sales, transfers
or other dispositions. Notwithstanding the foregoing, the terms of this Section 5.1(b) shall not
apply to any Cash Transaction, which shall be governed by the provisions of Section 7.

               (c) In case the Company shall fix a payment date for the making of a distribution to all
holders of Common Stock (including any such distribution made in connection with a consolidation or
merger in which the Company is the continuing corporation) of evidences of indebtedness or assets
(other than cash dividends or cash distributions payable out of consolidated earnings or earned
surplus or dividends or distributions referred to in Section 5.1(a)), or subscription rights or
warrants, the Exercise Price to be in effect after such payment date shall be determined by
multiplying the Exercise Price in effect immediately prior to such payment date by a fraction, the
numerator of which shall be the total number of shares of Common Stock outstanding multiplied by
the Exercise Price (as defined below) per share of Common Stock immediately prior to such payment
date, less the fair market value (as determined by the Company’s Board of Directors in good faith)
of said assets or evidences of indebtedness so distributed, or of such subscription rights or
warrants, and the denominator of which shall be the total number of shares of Common Stock
outstanding multiplied by the Fair Market Value per share of Common Stock immediately prior to such
payment date. Notwithstanding the foregoing, in no case shall any adjustment pursuant to this
Section 5.1(c) result in an Exercise Price below $2.82 per Exercise Share (as adjusted for any
stock dividends, combinations, splits, recapitalizations and the like after the date hereof).

     5.2 Anti-dilution.

               (a) If at any time or from time to time after the date hereof, the Company issues or sells, or
is deemed by the express provisions of this Section 5.2 to have issued or sold, Additional Shares
of Common Stock (as defined in Section 5.2(d) below), other than pursuant to any event as provided
in Section 5.1 above, for an Effective Price (as defined in Section 5.2(e) below) less than the
then effective Exercise Price, then and in each such case the then effective Exercise Price shall
be reduced, as of the opening of business on the date of such

7.

 

issue or sale, to a price determined by multiplying the then effective Exercise Price by
a fraction (i) the numerator of which shall be (A) the number of shares of Common Stock deemed
“outstanding” (as defined below) immediately prior to such issue or sale, plus (B) the number of
shares of Common Stock which the aggregate consideration received or deemed to be received (as
computed in Section 5.2(b) below) by the Company for the total number of Additional Shares of
Common Stock so issued would purchase at such then effective Exercise Price, and (ii) the
denominator of which shall be the number of shares of Common Stock deemed “outstanding” (as defined
below) immediately prior to such issue or sale plus the total number of Additional Shares of Common
Stock so issued or deemed issued. For the purposes of the preceding sentence, the number of shares
of Common Stock deemed “outstanding” as of a given date shall be the sum of (A) the number of
shares of Common Stock actually outstanding, plus (B) the number of shares of Common Stock into
which the then outstanding shares of Exercise Shares could be converted if fully converted on the
day immediately preceding the given date, plus (C) the number of shares of Common Stock which could
be obtained through the exercise or conversion of all other rights, options and convertible
securities outstanding on the day immediately preceding the given date. Notwithstanding the
foregoing, in no case shall any adjustment pursuant to this Section 5.2 result in an Exercise Price
below $2.82 per Exercise Share (as adjusted for any stock dividends, combinations, splits,
recapitalizations and the like after the date hereof).

               (b) For the purpose of making any adjustment required under this Section 5.2, the
consideration received by the Company for any issue or sale of securities shall (A) to the extent
it consists of cash, be computed at the net amount of cash received by the Company after deduction
of any underwriting or similar commissions, compensation or concessions paid or allowed by the
Company in connection with such issue or sale but without deduction of any expenses payable by the
Company, (B) to the extent it consists of property other than cash, be computed at the fair value
of that property as determined in good faith by the Company’s
Board of Directors (the “Board”), and
(C) if Additional Shares of Common Stock, Convertible Securities (as defined in Section 5.2(c)) or
rights or options to purchase either Additional Shares of Common Stock or Convertible Securities
are issued or sold together with other stock or securities or other assets of the Company for a
consideration which covers both, be computed as the portion of the consideration so received that
may be reasonably determined in good faith by the Board to be allocable to such Additional Shares
of Common Stock, Convertible Securities or rights or options.

               (c) For the purpose of the adjustment required under this Section 5.2, if the Company issues
or sells (i) stock or other securities convertible into Additional Shares of Common Stock (such
convertible stock or securities being herein referred to as “Convertible Securities”) or (ii)
rights or options for the purchase of Additional Shares of Common Stock or Convertible Securities
and if the Effective Price of such Additional Shares of Common Stock is less than the then
effective Exercise Price, in each case the Company shall be deemed to have issued at the time of
the issuance of such rights or options or Convertible Securities the maximum number of Additional
Shares of Common Stock issuable upon exercise or conversion thereof (assuming the satisfaction of
any conditions to convertibility, exercisability or exchangeability (including, without limitation,
the passage of time)) and to have received as consideration for the issuance of such shares an
amount equal to the total amount of the consideration, if any, received by the Company for the
issuance of such rights or options or

8.

 

Convertible Securities, plus, in the case of such rights or options, the minimum amounts of
consideration, if any, payable to the Company upon the exercise of such rights or options, plus, in
the case of Convertible Securities, the minimum amounts of consideration, if any, payable to the
Company (other than by cancellation of liabilities or obligations evidenced by such Convertible
Securities) upon the conversion thereof; provided that if in the case of Convertible Securities the
minimum amounts of such consideration cannot be ascertained, but are a function of antidilution or
similar protective clauses, the Company shall be deemed to have received the minimum amounts of
consideration without reference to such clauses; provided further that if the minimum amount of
consideration payable to the Company upon the exercise or conversion of rights, options or
Convertible Securities is reduced over time or on the occurrence or non-occurrence of specified
events other than by reason of antidilution adjustments, the Effective Price shall be recalculated
using the figure to which such minimum amount of consideration is reduced. No further adjustment
of the then effective Exercise Price, as adjusted upon the issuance of such rights, options or
Convertible Securities, shall be made as a result of the actual issuance of Additional Shares of
Common Stock on the exercise of any such rights or options or the conversion of any such
Convertible Securities.

               (d) “Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the
Company or deemed to be issued pursuant to this Section 5.2, other than:

                    (i) shares of Common Stock and/or options, warrants, Convertible Securities or other Common
Stock purchase rights and the Common Stock issuable pursuant to such options, warrants or other
rights (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like
after the date hereof) to employees, officers or directors of, or consultants or advisors to the
Company or any subsidiary, pursuant to stock purchase or stock option plans or other arrangements
that are approved by the Board;

                    (ii) shares of Common Stock and/or options, warrants, Convertible Securities or other Common
Stock purchase rights and the Common Stock issued or issuable after the date hereof pursuant to
such options, warrants or other rights (as adjusted for any stock dividends, combinations, splits,
recapitalizations and the like after the date hereof) for consideration other than cash pursuant to
a merger, consolidation, acquisition or similar business combination, provided that such
transaction is not for capital raising purposes rather than strategic purposes;

                    (iii) shares of Common Stock and/or options, warrants, Convertible Securities or other Common
Stock purchase rights and the Common Stock issued or to be issued after the date hereof pursuant to
such options, warrants or other rights (as adjusted for any stock dividends, combinations, splits,
recapitalizations and the like after the date hereof) pursuant to any event as provided in Section
5.1 above;

                    (iv) shares of Common Stock and/or options, warrants, Convertible Securities or other Common
Stock purchase rights and the Common Stock issued or to be issued after the date hereof pursuant to
such options, warrants or other rights (as adjusted for any stock dividends, combinations, splits,
recapitalizations and the like after the date hereof)

9.

 

by the Company in a public offering pursuant to a registration statement filed under the
Securities Act; and

                    (v) shares of Common Stock and/or options, warrants, Convertible Securities or other Common
Stock purchase rights and the Common Stock issued or to be issued after the date hereof pursuant to
such options, warrants or other rights (as adjusted for any stock dividends, combinations, splits,
recapitalizations and the like after the date hereof) in connection with strategic transactions
involving the Company and other entities, including, without limitation (i) joint ventures,
partnering, manufacturing, marketing or distribution arrangements or (ii) licensing, intellectual
property transfer or development arrangements; provided that such transaction is not substantially
for equity financing purposes.

               (e) The “Effective Price” of Additional Shares of Common Stock shall mean the quotient
determined by dividing the total number of Additional Shares of Common Stock issued or sold, or
deemed to have been issued or sold by the Company under this Section 5.2, into the aggregate
consideration received, or deemed to have been received by the Company for such issue under this
Section 5.2, for such Additional Shares of Common Stock.

     6. Fractional Shares. No fractional shares shall be issued upon the exercise of this
Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including
fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation,
the exercise would result in the issuance of a fractional share, the Company shall, in lieu of
issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash
equal to the product resulting from multiplying the then current Fair Market Value of an Exercise
Share by such fraction.

     7. Automatic Exercise and Termination. In the event of, at any time during the
Exercise Period, any reorganization, reclassification, consolidation, merger, sale, transfer or
other disposition contemplated in Section 5.1(c) in which the consideration paid is in the form of
cash (a “Cash Transaction”), the Company shall provide to the Holder ten (10) days advance written
notice of such Cash Transaction, and this Warrant shall terminate unless exercised prior to the
occurrence of such Cash Transaction. In connection with the consummation of a Cash Transaction, the
Company (or the successor entity) shall purchase this Warrant from the Holder by paying to the
Holder, within five days of such consummation, cash in an amount equal to the Black-Scholes Value
(as defined below) of the remaining unexercised portion of this Warrant. “Black-Scholes Value”
means the value of the unexercised portion of this Warrant calculated using the
Black-Scholes Option Pricing Model determined as of the day immediately following the public
announcement of the applicable Cash Transaction and reflecting (i) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as
of the date of such request and (ii) an expected volatility equal to the 100 day volatility
obtained from the HVT function on Bloomberg.

     8. Termination Extension. If the Company fails to cause any Registration Statement
covering Registrable Securities (as defined in the Purchase Agreement) to be declared effective
prior to the applicable dates set forth therein, or if any event requiring payment of a Penalty (as
defined in the Purchase Agreement) occurs, then the Exercise Period of this Warrant

10.

 

shall be extended one day for each day that a Penalty is payable by the Company.
Notwithstanding the foregoing, under no circumstances shall the Exercise Period be extended to a
date later than August 20, 2012.

     9. No Stockholder Rights. This Warrant in and of itself shall not entitle the Holder
to any voting rights or other rights as a stockholder of the Company.

     10. Transfer of Warrant. Subject to applicable laws and the restriction on transfer
set forth on the first page of this Warrant, this Warrant and all rights hereunder are
transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant
and the form of assignment attached hereto to any transferee designated by Holder. The transferee
shall sign an investment letter in form and substance satisfactory to the Company.

     11. Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen,
mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or
destroyed. Any such new Warrant shall constitute an original contractual obligation of the
Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any
time enforceable by anyone.

     12. Notices, etc. All notices required or permitted hereunder shall be in writing
and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b)
when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if
not, then on the next business day, (c) five days after having been sent by registered or certified
mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt.
All communications shall be sent to the Company at the address listed on the signature page and to
the Holders at the addresses on the Company records, or at such other address as the Company or
Holder may designate by advance written notice to the other parties hereto.

     13. Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to all of the terms and conditions contained herein.

     14. Governing Law. This Warrant and all rights, obligations and liabilities
hereunder shall be governed by the laws of the State of California without regard to the principles
of conflict of laws.

11.

 

     In Witness Whereof, the Company has caused this Warrant to be executed by its duly
authorized officer as of February 20, 2007.

	 	 	 	 	 
	 	

IDM Pharma, Inc.

 	 
	 	By:  	 	 
	 	 	Name:  	Jean-Loup Romet-Lemonne 	 
	 	 	Title:  	Chief Executive Officer 	 

	 	Address:	 	9 Parker, Suite 100

Irvine, CA 92618

Facsimile: (949) 470-6439

[Warrant Signature Page]

 

 

NOTICE OF EXERCISE

TO: IDM Pharma, Inc.

     (1) o The undersigned hereby elects to purchase                      shares of the Common Stock of
IDM Pharma, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any.

          o
The undersigned hereby elects to purchase                      shares of the Common Stock of the
Company pursuant to the terms of the net exercise provisions set forth in Section 2.2 of the
attached Warrant, and shall tender payment of all applicable transfer taxes, if any.

     (2) Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below:

                                                            

(Name)

                                                            

                                                            

(Address)

     (3) The undersigned represents that (i) the aforesaid shares of Common Stock are being
acquired for the account of the undersigned for investment and not with a view to, or for resale in
connection with, the distribution thereof and that the undersigned has no present intention of
distributing or reselling such shares; (ii) the undersigned is aware of the Company’s business
affairs and financial condition and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision regarding its investment in the Company; (iii) the
undersigned is experienced in making investments of this type and has such knowledge and background
in financial and business matters that the undersigned is capable of evaluating the merits and
risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned
understands that the shares of Common Stock issuable upon exercise of this Warrant have not been
registered under the Securities Act of 1933, as amended (the
“Securities Act”), by reason of a
specific exemption from the registration provisions of the Securities Act, which exemption depends
upon, among other things, the bona fide nature of the investment intent as expressed herein, and,
because such securities have not been registered under the Securities Act, they must be held
indefinitely unless subsequently registered under the Securities Act or an exemption from such
registration is available; (v) the undersigned is aware that the aforesaid shares of Common Stock
may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are
met and until the undersigned has held the shares for the number of years prescribed by Rule 144,
that among the conditions for use of the Rule is the availability of current information to the
public about the Company and the Company has not made such information available and has no present
plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of
the aforesaid shares of Common Stock unless and until there is then in effect a registration
statement under the Securities Act covering

1.

 

such proposed disposition and such disposition is made in accordance with said registration
statement, and the undersigned will not make any sale, transfer or other disposition of the
aforesaid shares of Common Stock in violation of federal or state securities laws.

	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

(Date)

	 	 	 	 

(Signature)
	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 

(Print name)
	 	 

2.

 

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form
and supply required information. Do not use this
form to

purchase shares.)

     For Value Received, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to

	 	 	 
	Name:
	 	 
	 

	 	 

(Please Print)

	 	 	 
	Address:
	 	 
	 

	 	 

(Please Print)

Dated:                     , 20__

	 	 	 	 	 
	Holder’s

Signature:
	 	 	 	 
	 

	 	 

	 	 
	Holder’s

Address:
	 	 	 	 
	 

	 	 

	 	 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.

1.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]